日本臨牀 別冊 腎臓症候群(第3版)III

出版社: 日本臨牀社
発行日: 2022-10-31
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 腎臓症候群(第3版)III
電子書籍版: 2022-10-31 (第3版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

22,000 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

22,000 円(税込)

目次

  • 特集 腎臓症候群(第3版)III
       ―その他の腎臓疾患を含めて―

    IX.各種病態にみられる腎障害
     1.内分泌疾患
      (1)サブクリニカルクッシング症候群とクッシング症候群
      (2)偽性副甲状腺機能低下症
      (3)原発性アルドステロン症(Conn症候群)・家族性アルドステロン症
      (4)原発性副甲状腺機能亢進症
      (5)甲状腺疾患
      (6)低レニン性低アルドステロン症
      (7)副腎皮質機能不全と水・電解質代謝異常
     2.代謝性疾患,電解質異常
      (1)ミルクアルカリ症候群
      (2)高シュウ酸尿症
      (3)高尿酸血症に伴う腎障害
      (4)血清カリウム異常と腎臓病
      (5)糖尿病性腎症
      (6)糖尿病性腎臓病
      (7)糖尿病に伴う病理組織
      (8)肥満関連腎症
     3.造血器疾患
      (1)Castleman病・TAFRO症候群
      (2)POEMS症候群
      (3)von Willebrand病―腎疾患との関連も含めて―
      (4)クリオグロブリン血症
      (5)悪性リンパ腫
      (6)巨大血小板性血小板減少症
      (7)原発性マクログロブリン血症における腎障害
      (8)細小血管障害性溶血性貧血,微小血管性溶血性貧血
      (9)成人T細胞白血病・リンパ腫
      (10)多発性骨髄腫
      (11)単クローン性免疫グロブリン沈着症
      (12)特発性形質細胞性リンパ節症(IPL)に伴う腎病変
      (13)播種性血管内凝固症候群
      (14)白血病と腎障害
      (15)発作性夜間血色素尿症における腎障害
      (16)志賀毒素産生大腸菌による溶血性尿毒症症候群(STEC-HUS)
      (17)腎意義の単クローン性ガンマグロブリン血症(MGRS)による尿細管間質疾患
     4.膠原病,血管炎
      (1)ANCA関連腎炎
      (2)Behcet病の腎障害
      (3)好酸球性多発血管炎性肉芽腫症(Churg-Strauss症候群)
      (4)シェーグレン症候群の腎病変
      (5)成人Still病
      (6)多発血管炎性肉芽腫症(Wegener肉芽腫症)
      (7)関節リウマチ
      (8)全身性強皮症
      (9)結節性多発動脈炎
      (10)顕微鏡的多発血管炎
      (11)抗リン脂質抗体症候群の腎合併症
      (12)混合性結合組織病(MCTD)
      (13)紫斑病性腎炎(IgA血管炎)
      (14)重複(オーバーラップ)症候群
      (15)全身性エリテマトーデス
      (16)多発性筋炎・皮膚筋炎における腎障害
      (17)高安動脈炎
     5.肝疾患,消化管疾患
      (1)炎症性腸疾患に伴う腎障害
      (2)肝腎症候群
      (3)原発性胆汁性胆管炎と腎障害
      (4)自己免疫性肝炎
      (5)Bile cast nephropathy/Cholemic nephropathy
     6.循環器疾患
      (1)急性心不全に合併する腎障害
      (2)感染性心内膜炎
      (3)心不全
     7.感染症
      (1)COVID-19と腎疾患
      (2)BKウイルスと移植腎障害
      (3)HIV関連腎症
      (4)MRSA関連糸球体腎炎
      (5)アデノウイルス感染症と腎尿路障害
      (6)エルシニア感染症による急性腎不全
      (7)クラミジア感染症
      (8)シャント腎炎
      (9)レプトスピラ感染症(Weil病)
      (10)マイコプラズマ感染症
      (11)日本におけるリケッチア感染症(つつが虫病と日本紅斑熱)
      (12)ロタウイルス胃腸炎と尿酸結石症
      (13)サイトメガロウイルス感染症と腎障害
      (14)肝炎ウイルス
      (15)気腫性腎盂腎炎
      (16)急性腎盂腎炎
      (17)腎マラコプラキア
      (18)腎原虫・寄生虫感染症
      (19)腎結核
      (20)腎膿瘍、腎周囲炎・腎周囲膿瘍腎
      (21)腎症候性出血熱
      (22)真菌尿路感染症(腎真菌感染症)
      (23)敗血症
      (24)閉塞性腎盂腎炎
      (25)溶連菌感染後急性糸球体腎炎
     8.その他の病態
      (1)アミロイドーシスと腎病変
      (2)サルコイドーシスと腎障害
      (3)移植後糸球体腎炎
      (4)横紋筋融解症の最新の病態メカニズムと診断
      (5)偽性アルドステロン症
      (6)好酸球性リンパ濾胞増殖症(木村病)
      (7)造血幹細胞移植後の血栓性微小血管障害症
      (8)泡沫細胞症候群
      (9)類天疱瘡

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

IX 各種病態にみられる腎障害

P.8 掲載の参考文献
1) Di Dalmazi G, et al : Subclinical hypercortisolism : a state, a syndrome, or a disease? Eur J Endocrinol 173 : M61-71, 2015.
3) Connell JM, et al : Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 5 : 425-433, 1987.
4) Davis JO, Howell DS : Comparative effect of ACTH, cortisone and DCA on renal function, electrolyte excretion and water exchange in normal dogs. Endocrinology 52 : 245-255, 1953.
5) Wen C, et al : Hemodynamic profile of corticotropin-induced hypertension in the rat. J Hypertens 16 : 187-194, 1998.
6) Koh JM, et al : Increased urinary albumin excretion in Cushing's syndrome : remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf) 52 : 349-353, 2000.
7) Haentjens P, et al : Glomerular filtration rate in patients with Cushing's disease : a matched case-control study. Eur J Endocrinol 153 : 819-829, 2005.
8) Bailey MA, et al : Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension 54 : 890-896, 2009.
9) Faggiano A, et al : Nephrolithiasis in Cushing's disease : prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab 88 : 2076-2080, 2003.
10) Ferrari P, et al : Modulation of renal calcium handling by 11β-hydroxysteroid dehydrogenase type 2. J Am Soc Nephrol 13 : 2540-2546, 2002.
11) Findling JW, et al : Vitamin D metabolites and parathyroid hormone in Cushing's syndrome : relationship to calcium and phosphorus homeostasis. J Clin Endocrinol Metab 54 : 1039-1044, 1982.
12) Knoepfelmacher M, et al : Resistance to vasopressin action on the kidney in patients with Cushing's disease. Eur J Endocrinol 137 : 162-166, 1997.
13) Garrod O, Burston RA : The diuretic response to ingested water in Addison's disease and panhypopituitarism and the effect of cortisone thereon. Clin Sci 11 : 113-128, 1952.
14) Kleeman CR, et al : Mechanisms of impaired water excretion in adrenal and pituitary insufficiency. I. The role of altered glomerular filtration rate and solute excretion. J Clin Invest 37 : 1799-1808, 1958.
15) Serio A, Fraioli A : Epidemiology of nephrolithiasis. Nephron 81 (Suppl 1) : 26-30, 1999
P.12 掲載の参考文献
1) Albright F, et al : Pseudohypoparathyroidism : An example of "Seabright-Bantam syndrome". Endocrinology 30 : 922-932, 1942.
3) Juppner H : Molecular Definition of Pseudohypoparathyroidism Variants. J Clin Endocrinol Metab 106 : 1541-1552, 2021.
5) Takatani R, et al : Prevalence of pseudohypoparathyroidism and nonsurgical hypoparathyroidism in Japan in 2017 : A nationwide survey. J Epidemiol, 2022. (DOI : 10.2188/jea.JE20220152)
8) 皆川真規 : 偽性副甲状腺機能低下症. 最新医学 71 : 1930-1935, 2016.
9) Mantovani G, et al : Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders : An Updated Practical Tool for Physicians and Patients. Horm Res Paediatr 93 : 182-196, 2020.
10) Miyakawa Y, et al : Language delay and developmental catch-up would be a clinical feature of pseudohypoparathyroidism type 1A during childhood. Endocr J 66 : 215-221, 2019.
11) 尾形悦郎, ほか : ヒトPTH- (1-34) によるEllsworth-Howard試験の実施法と判定基準-副甲状腺機能低下症患者における検討-. 日本内分泌学会雑誌 60 : 971-984, 1984.
13) Thiele S, et al : From pseudohypoparathyroidism to inactivating PTH/PTHrP signaling disorder (iPPSD), a novel classification proposed by the EuroPHP netwok. Eur J Endocrinol 175 : P1-P17, 2016.
14) Neary NM, et al : Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab 97 : 3025-3030, 2012.
P.16 掲載の参考文献
1) Conn JW : Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 : 3-17, 1955.
2) Kayser SC, et al : Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism : A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 101 : 2826-2835, 2016.
3) Hannemann A, Wallaschofski H : Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature. Horm Metab Res 44 : 157-162, 2012.
4) Burrello J, et al : Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. Hypertension 75 : 1025-1033, 2020.
5) Ohno Y, et al ; Nagahama Study ; JPAS Study Group : Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism : A Multicenter Study in Japan. Hypertension 71 : 530-537, 2018.
7) Monticone S, et al : Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension : a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6 : 41-50, 2018.
8) Buffolo F, et al : Primary Aldosteronism and Obstructive Sleep Apnea : A Cross-Sectional Multi-Ethnic Study. Hypertension 74 : 1532-1540, 2019.
9) Zannaro MC, et al : An update on novel mechanisms of primary aldosteronism. J Endocrinol 224 : R63-R77, 2015.
10) 原発性アルドステロン症診療ガイドライン 2021. 日本内分泌学会雑誌 97 (Suppl) : 1-55, 2021.
11) Ozeki Y, et al : Development of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations. Diagnostics (Basel) 11 : 433, 2021.
16) Fu Y, et al : Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension 59 : 599-606, 2012.
17) Ren Y, et al : Aldosterone sensitizes connecting tubule glomerular feedback via the aldosterone receptor GPR30. Am J Physiol Renal Physiol 307 : F427-434, 2014.
18) 高橋克敏 : Masked chronic kidney disease in primary aldosteronism (masked CKD). 原発性アルドステロン症診療マニュアル 改訂第3版 (成瀬光栄, ほか編), p162-164, 診断と治療社, 2017.
19) Kobayashi H, et al ; JPAS/JRAS Study Group : Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function. Hypertension 74 : 630-638, 2019.
P.21 掲載の参考文献
1) Silverberg SJ, Bilezikian JP : Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 81 : 2036-2040, 1996.
2) Parks J, et al : Hyperparathyroidism in nephrolithiasis. Arch Intern Med 140 : 1479-1481, 1980.
3) Tay YD, et al : Occult urolithiasis in asymptomatic primary hyperparathyroidism. Endocr Res 43 : 106-115, 2018.
5) Tassone F, et al : Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism. J Clin Endocrinol Metab 94 : 4458-4461, 2009.
6) Rao DS, et al : Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89 : 5415-5422, 2004.
7) Bollerslev J, et al : Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism : a prospective, randomized trial. J Clin Endocrinol Metab 92 : 1687-1692, 2007.
8) Levi M, et al : Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest 71 : 1624-1632, 1983.
9) Lins LE : Reversible renal failure caused by hypercalcemia. A retrospective study. Acta Med Scand 203 : 309-314, 1978.
11) Koubaity O, et al : Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery 167 : 149-154, 2020.
12) Beysel S, et al : Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord 19 : 106, 2019.
13) Trunzo JA, et al : Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery 144 : 915-918 ; discussion 919, 2008.
P.25 掲載の参考文献
1) Iglesias P, et al : Thyroid dysfunction and kidney disease : An update. Rev Endocr Metab Disord 18 : 131-144, 2017.
2) Rhee CM, et al : The relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease. Nephrol Dial Transplant 30 : 282-287, 2015.
3) Feinstein EI, et al : Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol 2 : 70-76, 1982.
4) Brohee D, et al : Circulating immune complexes in various thyroid diseases. Clin Exp Immunol 36 : 379-383, 1979.
5) Santoro D, et al : Autoimmune Thyroiditis and Glomerulopathies. Front Endocrinol (Lausanne) 8 : 119, 2017.
6) Kocak G, et al : Coexistent findings of renal glomerular disease with Hashimoto's thyroiditis. Clin Endocrinol 76 : 759-762, 2012.
7) 大崎芳典, ほか : 日本人における1型糖尿病と自己免疫性甲状腺疾患-合併頻度とその発症様式-. 糖尿病 52 : 887-893, 2009.
8) Okuma H, et al : Systemic Sarcoidosis with Thyroid Involvement. Intern Med 56 : 2181-2186, 2017.
12) Davis J, et al : Lithium and nephrotoxicity : a literature review of approaches to clinical management and risk stratification. BMC Nephrol 19 : 305, 2018.
P.30 掲載の参考文献
1) 柿添豊, 向山政志 : 選択的低アルドステロン症 [高レニン・低レニン性] ; 副腎. アルドステロン異常症. 低アルドステロン症および類縁疾患. 別冊日本臨牀領域別症候群シリーズ No.2 内分泌症候群 (第3版) II, p136-140, 日本臨牀社, 2018.
3) Yorke E, et al : Aldosterone deficiency after unilateral adrenalectomy for Conn's syndrome : a case report and literature review. Int J Surg Case Rep 7C : 141-144, 2015.
4) Wilczynski C, et al : Selective Hypoaldosteronism : A Review. Endocr Pract 21 : 957-965, 2015.
5) Inada M, et al : Hyperpotassemia and bradycardia in a bedridden elderly woman with selective hypoaldosteronism associated with low renin activity. Intern Med 49 : 307-313, 2010.
6) Sousa AG, et al : Hyporeninemic hypoaldosteronism and diabetes mellitus : Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes 7 : 101-111, 2016.
8) Messaoudi S, et al : Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 350 : 266-272, 2012.
10) 柴田洋孝 : 偽性アルドステロン症. 日本内科学会雑誌 95 : 671-676, 2006.
11) White PC, et al : 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18 : 135-156, 1997.
P.36 掲載の参考文献
1) Melmed S, et al : Williams Textbook of Endocrinology, 13th ed, p524-533, Elsevier, Philadelphia, 2016.
2) 柳瀬敏彦, ほか : 厚生労働科学研究費補助金難治性疾患克服研究事業副腎ホルモン産生異常に関する調査研究副腎ホルモン産生異常症の全国疫学調査アジソン病, 副腎性サブクリニカルクッシング症候群の全国における実態調査, 平成22年度総合研究報告書, p139-146, 2011.
5) Ullian ME : The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res 41 : 55-64, 1999.
6) Merke DP, et al : Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343 : 1362-1368, 2000.
8) Saito T, et al : Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats. Am J Physiol Renal Physiol 279 : F502-508, 2000.
14) Johannsson G, et al : Adrenal insufficiency : review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 82 : 2-11, 2015.
15) Burman P, et al : Deaths among adult patients with hypopituitarism : hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab 98 : 1466-1475, 2013.
P.40 掲載の参考文献
1) Sippy BW : Gastric and duodenal ulcer : Medical cure by an efficient removal of gastric juice corrosion. JAMA 64 : 1625-1630, 1915.
2) Kirsner JB, Palmer WL : Alkalosis Complicating the Sippy Treatment of Peptic Ulcer : An Analysis of One Hundred and Thirty-Five Episodes. Arch Intern Med 69 : 789-807, 1942.
4) Jamieson MJ : Hypercalcaemia. Br Med J (Clin Res Ed) 290 : 378-382, 1985.
7) Zayed RF, et al : Calcium-Alkali Syndrome : Historical Review, Pathophysiology and Post-Modern Update. Cureus 13 : e13291, 2021.
8) Felsenfeld AJ, Levine B : Milk alkali syndrome and the dynamics of calcium homeostasis. Clin J Am Soc Nephrol 1 : 641-654, 2006.
9) Chapter 7 : Metabolic Alkalosis. In : Fluid, Electrolyte and Acid-Base Physiology, 5th ed (ed by Kamel KS, Halperin ML), p171-197, Elsevier, Philadelphia, 2017.
11) Good DW : Inhibition of bicarbonate absorption by peptide hormones and cyclic adenosine monophosphate in rat medullary thick ascending limb. J Clin Invest 85 : 1006-1013, 1990.
12) Weiner D, Verlander JW : Renal Acidification Mechanisms I. In : Brenner and Rector's The Kidney, 11th ed (ed by Yu ASL, et al), p247-273, Elsevier, Philadelphia, 2019.
13) Swanson CM, et al : Nicotine-substitute gum-induced milk alkali syndrome : a look at unexpected sources of calcium. Endocr Pract 19 : 142-144, 2013.
14) Yamagami K, et al : Pulmonary and gastric metastatic calcification due to milk-alkali syndrome : a case report. CEN Case Rep 2 : 209-214, 2013.
15) McMillan DE, Freeman RB : The milk alkali syndrome : a study of the acute disorder with comments on the development of the chronic condition. Medicine (Baltimore) 44 : 485-501, 1965.
P.45 掲載の参考文献
1) Bhasin B, et al : Primary and secondary hyperoxaluria : Understanding the enigma. World J Nephrol 4 : 235-244, 2015.
2) Cramer SD, Takayama T : Primary Hyperoxaluria. In : Genetic Diseases of the Kidney (ed by Lifton RP, et al), p571-586, Elsevier, Academic Press, San Diego, 2009.
5) Crivelli JJ, et al : Contribution of dietary oxalate and oxalate precursors to urinary oxalate excretion. Nutrients 13 : 62, 2020.
6) Morozumi M, Ogawa Y : Impact of dietary calcium and oxalate ratio on urinary stone formation in rats. Mol Urol 4 : 313-320, 2000.
8) Garrelfs SF, et al : Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 96 : 1389-1399, 2019.
12) Danpure CJ, Purdue PE : Primary hyperoxaluria. In : The Metabolic and Molecular Bases of Inherited Disease, 7th ed (ed by Scriver CR, et al), p2385-2424, McGraw-Hill, New York, 1995.
13) Li X, et al : A Putative Mutation Hotspot of the AGXT Gene Associated with Primary Hyperoxaluria Type 1 in the Chinese Population. Tohoku J Exp Med 246 : 233-241, 2018.
14) Williams HE, Smith LH Jr : L-glyceric aciduria. A new genetic variant of primary hyperoxaluria. N Engl J Med 278 : 233-238, 1968.
16) Belostotsky R, et al : Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87 : 392-399, 2010.
17) Sas DJ, et al : Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney Int 97 : 786-792, 2020.
19) Monico CG, et al : Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6 : 2289-2295, 2011.
20) Williams EL, et al : Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing. Mol Genet Genomic Med 3 : 69-78, 2015.
21) Liebow A, et al : An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol 28 : 494-503, 2017.
22) Ariceta G, et al : Hepatic Lactate Dehydrogenase A : An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep 6 : 1088-1098, 2021.
P.50 掲載の参考文献
1) 高尿酸血症・痛風の治療ガイドライン [第3版] (日本痛風・尿酸核酸学会ガイドライン改訂委員会編), 診断と治療社, 2018.
4) Li L, et al : Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? : A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15 : 122, 2014.
5) Kuwabara M, et al : Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function. Am J Nephrol 45 : 330-337, 2017.
9) Lanaspa MA, et al : Uric acid and hypertension. Hypertens Res 43 : 832-834, 2020.
10) Mogi M, et al : Update on Hypertension Research in 2021. Hypertens Res 45 : 1276-1297, 2022.
11) Barlow KA, Beilin LJ : Renal disease in primary gout. Q J Med 37 : 79-96, 1968.
12) Kohagura K, et al : An association between uric acid levels and renal arteriolopathy in chronic kidney disease : a biopsy-based study. Hypertens Res 36 : 43-49, 2013.
14) Fujii K, et al : Xanthine oxidase inhibitor ameliorates postischemic renal injury in mice by promoting resynthesis of adenine nucleotides. JCI Insight 4 : e124816, 2019.
16) Ejaz AA, et al : Hyperuricemia in Kidney Disease : A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage. Semin Nephrol 40 : 574-585, 2020.
17) Doria A, et al : Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med 382 : 2493-2503, 2020.
18) Badve SV, et al : Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med 382 : 2504-2513, 2020.
20) Sircar D, et al : Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia : A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis 66 : 945-950, 2015.
P.55 掲載の参考文献
1) Qiao Y, et al : Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med 180 : 718-726, 2020.
2) Fu EL, et al : Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes : A Nationwide Study. J Am Soc Nephrol 32 : 424-435, 2021.
3) Walther CP, et al : Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant 36 : 1893-1899, 2021.
4) エビデンスに基づくCKD 診療ガイドライン 2018 (日本腎臓学会編), p16, 東京医学社, 2018.
5) Korgaonkar S, et al : Serum potassium and outcomes in CKD : insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 5 : 762-769, 2010.
6) Wang HH, et al : Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease. PLoS One 8 : e67140, 2013.
7) Tanaka K, et al : Association between serum potassium levels and adverse outcomes in chronic kidney disease : the Fukushima CKD cohort study. Clin Exp Nephrol 25 : 410-417, 2021.
8) Kovesdy CP, et al : Serum potassium and adverse outcomes across the range of kidney function : a CKD Prognosis Consortium meta-analysis. Eur Heart J 39 : 1535-1542, 2018.
10) Ray PE, et al : Chronic potassium depletion induces renal injury, salt sensitivity, and hypertension in young rats. Kidney Int 59 : 1850-1858, 2001.
11) Zannad F, et al : Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia : the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail 7 : 54-64, 2020.
P.62 掲載の参考文献
1) Olivarius Nde F, et al : Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia 36 : 1007-1016, 1993.
2) Stevens PE, et al : Evaluation and management of chronic kidney disease : synopsis of the kidney disease : improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158 : 825-830, 2013.
4) Kume S, et al : Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig 10 : 1032-1040, 2019.
9) Perkovic V, et al : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380 : 2295-2306, 2019.
10) Wheeler DC, et al : Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9 : 22-31, 2021.
11) Cea Soriano L, et al : Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes : associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol 14 : 38, 2015.
12) Bentata Y, et al : Albuminuria in type 2 diabetes mellitus : from remission to progression. Ren Fail 38 : 481-483, 2016.
13) Yokoyama H, et al : Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 36 : 3227-3233, 2013.
14) Coresh J, et al : Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311 : 2518-2531, 2014.
15) Rossing K, et al : Progression of nephropathy in type 2 diabetic patients. Kidney Int 66 : 1596-1605, 2004.
16) Jardine MJ, et al : Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply. N Engl J Med 381 : 1089-1090, 2019.
P.68 掲載の参考文献
2) Retnakaran R, et al : Risk factors for renal dysfunction in type 2 diabetes : U.K. Prospective Diabetes Study 74. Diabetes 55 : 1832-1839, 2006.
3) Thomas MC, et al : Diabetic kidney disease. Nat Rev Dis Primers 1 : 15018, 2015.
4) Kume S, et al : Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig 10 : 1032-1040, 2019.
5) Tanaka N, et al : Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes. Diabetol Int 10 : 279-287, 2019.
6) Shikata K, et al : Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes : The Japan Diabetes Complication and its Prevention prospective study 5. J Diabetes Investig 11 : 325-332, 2020.
7) 糖尿病性腎症合同委員会 : 糖尿病性腎症病期分類2014の策定 (糖尿病性腎症病期分類改訂) について. 日本腎臓学会誌 56 : 547-552, 2014.
9) Yamanouchi M, et al : Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease : A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study. Diabetes Care 42 : 891-902, 2019.
10) Oshima M, et al : Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes. PLoS One 13 : e0201535, 2018.
11) Ueki K, et al : Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5 : 951-964, 2017.
12) Ueki K, et al : Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int 99 : 256-266, 2021.
13) Heerspink HJL, et al : Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383 : 1436-1446, 2020.
14) Gilbert RE : Proximal Tubulopathy : Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. Diabetes 66 : 791-800, 2017.
15) Bakris GL, et al : Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 383 : 2219-2229, 2020.
P.74 掲載の参考文献
2) 厚生労働科学研究費補助金難治性疾患等克服研究事業 (腎疾患実用化研究事業) 「糖尿病性腎症ならびに腎硬化症の診療水準向上と重症化防止にむけた調査・研究」研究班 (研究代表者 : 和田隆志) 糖尿病性腎症と高血圧性腎硬化症の病理診断への手引き. 日本腎臓学会誌 57 : 649-725, 2015.
3) 糖尿病性腎症病期分類に基づいた腎病理診断の手引き日本医療研究開発機構研究費 (腎疾患実用化研究事業) 「糖尿病性腎症の進展予防にむけた病期分類-病理-バイオマーカーを統合した診断法の開発」 (和田隆志, ほか編), 東京医学社, 2019.
4) 一般社団法人日本腎臓学会 : エビデンスに基づくCKD診療ガイドライン 2018 第16章 糖尿病性腎臓病 (DKD) : 前文. 日本腎臓学会誌 60 : 1164-1165, 2018.
5) Oshima M, et al : Trajectories of kidney function in diabetes : a clinicopathological update. Nat Rev Nephrol 17 : 740-750, 2021.
6) 和田隆志, ほか : 糖尿病患者の腎障害. 内科学書 [改訂第9版] (南学正臣総編集), p561-563, 中山書店, 2019.
8) Furuichi K, et al : Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant 33 : 138-148, 2018.
9) Hoshino J, et al : A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS One 13 : e0190923, 2018.
12) Yamanouchi M, et al : Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease : A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study. Diabetes Care 42 : 891-902, 2019.
13) Furuichi K, et al : Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy. BMJ Open Diabetes Res Care 8 : 2020.
14) 清水美保, 和田隆志 : DKDの病理学的特徴. 日本内科学会雑誌 108 : 907-915, 2019.
15) Sharma SG, et al : The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 8 : 1718-1724, 2013.
16) 清水美保, 和田隆志 : 糖尿病性腎症ならびに糖尿病に合併するネフローゼ症候群. 日本腎臓学会誌 56 : 500-509, 2014.
17) Fiorentino M, et al : Renal biopsy in patients with diabetes : a pooled meta-analysis of 48 studies. Nephrol Dial Transplant 32 : 97-110, 2017.
P.79 掲載の参考文献
1) Ochiai H, et al : Association of the combination of weight gain after 20 years of age and current obesity with chronic kidney disease in Japan : a cross-sectional study. BMJ Open 9 : e027752, 2019.
2) Chen HM, et al : Obesity-related glomerulopathy in China : a case series of 90 patients. Am J Kidney Dis 52 : 58-65, 2008.
3) Chang AR, et al : Adiposity and risk of decline in glomerular filtration rate : meta-analysis of individual participant data in a global consortium. BMJ 364 : k5301, 2019.
4) Okabayashi Y, et al : Glomerulopathy Associated With Moderate Obesity. Kidney Int Rep 1 : 250-255, 2016.
5) Hashimoto Y, et al : Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol 10 : 578-583, 2015.
6) Sakurai M, et al : Sex Differences in Associations Among Obesity, Metabolic Abnormalities, and Chronic Kidney Disease in Japanese Men and Women. J Epidemiol 26 : 440-446, 2016.
7) Wei L, et al : Obesity-Related Glomerulopathy : From Mechanism to Therapeutic Target. Diabetes Metab Syndr Obes 14 : 4371-4380, 2021.
8) Kanzaki G, et al : New insights on glomerular hyperfiltration : a Japanese autopsy study. JCI Insight 2 : e94334, 2017.
9) Hughson MD, et al : Associations of glomerular number and birth weight with clinicopathological features of African Americans and whites. Am J Kidney Dis 52 : 18-28, 2008.
11) Tsuboi N, et al : Low glomerular density with glomerulomegaly in obesity-related glomerulopathy. Clin J Am Soc Nephrol 7 : 735-741, 2012.
12) Conley MM, et al : Interventions for weight loss in people with chronic kidney disease who are overweight or obese. Cochrane Database Syst Rev 3 : CD013119, 2021.
14) Xie Y, et al : Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes : Emulation of a Target Trial Using Health Care Databases. Diabetes Care 43 : 2859-2869, 2020.
15) Huang H, et al : Improvement of Renal Function After Bariatric Surgery : a Systematic Review and Meta-analysis. Obes Surg 31 : 4470-4484, 2021.
P.85 掲載の参考文献
2) Fajgenbaum DC, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017.
3) Waterston A, Bower M : Fifty years of multicentric Castleman's disease. Acta Oncol 43 : 698-704, 2004.
5) Xu D, et al : Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant 27 (Suppl 3) : iii119-125, 2012.
6) Tosaki T, et al : Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease. CEN Case Rep 10 : 265-272, 2021.
7) Masaki Y, et al : Castleman disease and TAFRO syndrome. Ann Hematol 101 : 485-490, 2022.
8) Iwaki N, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016.
10) Shimada K, et al : TAFRO Syndrome With Kidney Involvement : A Case Series of Patients With Kidney Biopsies. Kidney Med 3 : 286-293, 2021.
11) Mizuno H, et al : The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome. Kidney Int Rep 5 : 1172-1179, 2020.
12) van Rhee F, et al : International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 : 2115-2124, 2018.
P.89 掲載の参考文献
1) 中世古知昭, 大和田千佳子 : POEMS症候群の診断と治療. 日本臨牀 78 (増刊 : 造血器腫瘍学 (第2版) : 658-663, 2020.
4) 新保慎一郎, ほか : 多発性神経炎および内分泌異常を惹起した孤立性骨髄腫. 日本臨牀 26 : 2444-2456, 1968.
7) 納光弘, ほか : Crow-Fukase症候群の全国疫学調査 2004. 厚生労働省免疫性神経に関する調査研究班平成16年度報告書, p141-144.
10) Nakamoto Y, et al : A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 14 : 2370-2386, 1999.
11) Nakamura Y, et al : A patient with POEMS syndrome : the pathology of glomerular microangiopathy. Tohoku J Exp Med 231 : 229-234, 2013.
12) 大橋隆治 : POEMS症候群 (Crow-Fukase症候群) -腎臓専門医の視点より. 腎と透析 86 (増刊号) : 302-306, 2019.
13) Faizan U, et al : Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome-A Systematic Review. Clin Lymphoma Myeloma Leuk 22 : e26-e33, 2022.
P.93 掲載の参考文献
1) 松下正 : von Willebrand病のマネジメント. 臨床血液 62 : 435-444, 2021.
2) 秋元哲 : von Willebrand病-腎疾患との関連も含めて- ; 各種病態にみられる腎障害. 造血器疾患. 別冊日本臨牀新領域別症候群シリーズ No.18 腎臓症候群 (第2版) 下, p390-393, 日本臨牀社, 2012.
3) 高橋芳右 : von Willebrand病の診断と治療. 日本血栓止血学会誌 18 : 572-574, 2007.
5) Kumar S, et al : Acquired von Willebrand's syndrome : a single institution experience. Am J Hematol 72 : 243-247, 2003.
6) 嶋緑倫 : 後天性血友病・後天性von Willebrand病の診断と治療. 日本血栓止血学会誌 18 : 575-579, 2007.
7) Sugase T, et al : Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome : A Case of a Patient With Membranous Nephropathy. Clin Med Insights Case Rep 11 : 1179547618763371, 2018.
8) 日本血栓止血学会/標準化委員会/VWF/TTP部会 ; 西野正人, ほか : 本邦におけるvon Willebrand 病患者調査報告. 日本血栓止血学会誌 19 : 311-318, 2008.
9) 佐藤昌史, ほか : 血尿にて発見されたvon Willebrand病の1例と血小板Epinephrine凝集抑制を共にもつ1家系. 姫路赤十字病院誌 16 : 12-22, 1992.
11) 秋元哲, 草野英二 : 血栓性微小血管症. 腎と透析 69 (増刊) : 433-435, 2010.
13) Hernandez E, et al : Elevation of von Willebrand factor levels in patients with IgA nephropathy : effect of ACE inhibition. Am J Kidney Dis 30 : 397-403, 1997.
14) van der Vorm LN, et al : Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-stage renal disease. Clin Kidney J 13 : 72-74, 2020.
15) von Willebrand病の診療ガイドライン作成委員会 : von Willebrand病の診療ガイドライン 2021年版. 日本血栓止血学会誌 32 : 413-481, 2021.
P.98 掲載の参考文献
1) 日本循環器学会, ほか : 血管炎症候群の診療ガイドライン (2017年改訂版), 2018.
4) Terrier B, et al : The spectrum of type I cryoglobulinemia vasculitis : new insights based on 64 cases. Medicine (Baltimore) 92 : 61-68, 2013.
5) Silva F, et al : New insights in cryoglobulinemic vasculitis. J Autoimmun 105 : 102313, 2019.
6) Roccatello D, et al : Cryoglobulinaemia. Nat Rev Dis Primers 4 : 11, 2018.
9) Zaidan M, et al : Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. J Am Soc Nephrol 27 : 1213-1224, 2016.
10) Fogo AB, et al : AJKD Atlas of Renal Pathology : Cryoglobulinemic Glomerulonephritis. Am J Kidney Dis 67 : e5-7, 2016.
12) Muchtar E, et al : How I treat cryoglobulinemia. Blood 129 : 289-298, 2017.
P.103 掲載の参考文献
1) 李宗泰, ほか : 悪性リンパ腫123例における, 電解質異常と腎病変の臨床病理学的検討. 臨床血液 32 : 1527-1532, 1991.
2) Lanore JJ, et al : Hemodialysis for acute renal failure in patients with hematologic malignancies. Crit Care Med 19 : 346-351, 1991.
3) 松井美詠子, ほか : 急性腎不全とネフローゼ症候群を合併した悪性リンパ腫. 臨床血液 31 : 229-233, 1990.
4) Mekori YA, et al : Acute anuric bilateral ureteral obstruction in malignant lymphoma. Am J Med Sci 287 : 70-73, 1984.
5) Mallouk A, et al : Concurrent FSGS and Hodgkin's lymphoma : case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol 10 : 284-289, 2006.
6) Cil T, et al : Prevalence of antineutrophil cytoplasmic antibody positivity in patients with Hodgkin's and non-Hodgkin lymphoma : a single center experience. Int J Hematol 90 : 52-57, 2009.
7) Doussis-Anagnostopoulou IA, et al : Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 197 : 677-683, 2002.
8) Da'as N, et al : Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia : a retrospective study in 700 patients. Eur J Haematol 67 : 158-164, 2001.
9) Luciano RL, Brewster UC : Kidney involvement in leukemia and lymphoma. Adv Chronic Kidney Dis 21 : 27-35, 2014.
10) Harris KP, et al : Acute renal failure associated with haematological malignancies : a review of 10 years experience. Eur J Haematol 47 : 119-122, 1991.
11) Patel TV, et al : A forgotten cause of kidney injury in chronic myelomonocytic leukemia. Am J Kidney Dis 54 : 159-164, 2009.
12) 高橋徹, ほか : 高Ca血症をきたした造血器腫瘍の検討. 臨床血液 27 : 2070-2077, 1986.
13) Wilson FP, Berns JS : Onco-nephrology : tumor lysis syndrome. Clin J Am Soc Nephrol 7 : 1730-1739, 2012.
14) Cirillo P, et al : Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 20 : 545-553, 2009.
P.109 掲載の参考文献
2) Peterson LC, et al : Fechtner syndrome-a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 65 : 397-406, 1985.
3) May R : Leukozyteneinschlusse. Dtsch Arch Klin Med 96 : 1-6, 1909.
4) Hegglin R : Simultaneous Constitutional Changes In Neutrophils and Platelets. Helv Med Acta 12 : 439, 1945.
6) Kelley MJ, et al : Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet 26 : 106-108, 2000.
7) Seri M, et al : Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet 26 : 103-105, 2000.
8) Kunishima S, et al : Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 97 : 1147-1149, 2001.
11) Seri M, et al : MYH9-related disease : May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82 : 203-215, 2003.
12) 國島伸治 : Epstein症候群 ; 血小板の異常. 血小板減少症. その他の血小板減少症. 別冊日本臨牀新領域別症候群シリーズ No.22 血液症候群 (第2版) II, p372-374, 日本臨牀社, 2013.
13) Savoia A, et al : Heavy chain myosin 9-related disease (MYH9-RD) : neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 103 : 826-832, 2010.
14) Pecci A, et al : MYH9 : Structure, functions and role of non-muscle myosin IIA in human disease. Gene 664 : 152-167, 2018.
15) Savoia A, Pecci A : MYH9-Related Disease. In : GeneReviews(R) [Internet] (ed by Adam MP, et al), University of Washington, Seattle ; 1993-2022, 2008 Nov 20 [updated 2021 Feb 18].
16) Noris P, et al : Platelet diameters in inherited thrombocytopenias : analysis of 376 patients with all known disorders. Blood 124 : e4-e10, 2014.
19) Pecci A, et al : MYH9-related disease : a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat 35 : 236-247, 2014.
20) Miura K, et al : Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis. Nephrol Dial Transplant 28 : 2993-3003, 2013.
21) Johnstone DB, et al : Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy. Mol Cell Biol 31 : 2162-2170, 2011.
22) Suzuki N, et al : Establishment of mouse model of MYH9 disorders : heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability. PLoS One 8 : e71187, 2013.
23) Verver EJ, et al : Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease. Ear Hear 37 : 112-120, 2016.
24) 難病情報センター : エプスタイン症候群 (指定難病287). [www.nanbyou.or.jp/entry/4652]
25) Hashimoto J, et al : Successful Kidney Transplantation in Epstein Syndrome With Antiplatelet Antibodies and Donor-specific Antibodies : A Case Report. Transplant Proc 47 : 2541-2543, 2015.
27) Zaninetti C, et al : Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia. Am J Hematol 94 : E199-E201, 2019.
P.114 掲載の参考文献
1) Treon SP, et al : MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 367 : 826-833, 2012.
3) Banwait R, et al : Extramedullary Waldenstrom macroglobulinemia. Am J Hematol 90 : 100-104, 2015.
4) Vos JM, et al : Renal disease related to Waldenstrom macroglobulinaemia : incidence, pathology and clinical outcomes. Br J Haematol 175 : 623-630, 2016.
5) Uppal NN, et al : Kidney diseases associated with Waldenstrom macroglobulinemia. Nephrol Dial Transplant 34 : 1644-1652, 2019.
6) Salviani C, et al : Renal involvement in Waldenstrom's macroglobulinemia : case report and review of literature. Ren Fail 36 : 114-118, 2014.
9) Kyle RA, et al : Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 13 : 184-186, 2013.
10) Kaiser LM, et al : CXCR4 in Waldenstrom's Macroglobulinema : chances and challenges. Leukemia 35 : 333-345, 2021.
P.118 掲載の参考文献
2) 秋元哲, 草野英二 : 細小血管障害性溶血性貧血, 微小血管性溶血性貧血 ; 各種病態にみられる腎障害. 造血器疾患. 別冊日本臨牀新領域別症候群シリーズ No.18 腎臓症候群 (第2版) 下, p419-422, 日本臨牀社, 2012.
3) 森下英理子 : 細血管障害性溶血性貧血の診断と治療. 臨床血液 56 : 795-806, 2015.
4) 非典型溶血性尿毒症症候群診断基準改訂委員会, ほか : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015. 日本腎臓学会誌 58 : 62-75, 2016.
5) 池田洋一郎, 南学正臣 : 炎症・免疫機序による血栓止血のトピックス (2) 非典型溶血性尿毒症症候群 (aHUS). 炎症と免疫 29 : 453-457, 2021.
6) Miki T, et al : Anti-glomerular basement membrane glomerulonephritis complicated by thrombocytopenia. Intern Med 51 : 3395-3399, 2012.
7) Fujimura Y, Matsumoto M : Registry of 919 patients with thrombotic microangiopathies across Japan : database of Nara Medical University during 1998-2008. Intern Med 49 : 7-15, 2010.
9) van den Born BJ, et al : Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 51 : 862-866, 2008.
10) 加藤規利, ほか : 非典型溶血性尿毒症症候群 (aHUS) /血栓性血小板減少性紫斑病 (TTP). 腎と透析 91 : 94-102, 2021.
11) Rock GA, et al : Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325 : 393-397, 1991.
12) Mazepa MA, et al : How targeted therapy disrupts the treatment paradigm for acquired TTP : the risks, benefits, and unknowns. Blood 134 : 415-420, 2019.
13) 池田洋一郎 : aHUSの病態と治療の進歩. 炎症と免疫 29 : 497-503, 2021.
14) 高見昭良, ほか : 科学的根拠に基づいた血小板製剤の使用ガイドライン : 2019年改訂版. 日本輸血細胞治療学会誌 65 : 544-561, 2019.
15) Rizvi MA, et al : Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 40 : 896-901, 2000.
P.123 掲載の参考文献
1) Uchiyama T, et al : Adult T-cell leukemia : clinical and hematologic features of 16 cases. Blood 50 : 481-492, 1977.
2) Poiesz BJ, et al : Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77 : 7415-7419, 1980.
3) Hinuma Y, et al : Adult T-cell leukemia : antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 78 : 6476-6480, 1981.
4) Ito S, et al : Epidemiology of adult T-cell leukemia-lymphoma in Japan : An updated analysis, 2012-2013. Cancer Sci 112 : 4346-4354, 2021.
5) 松岡雅雄 : ヒトT細胞白血病ウイルス1型は何故, 成人T細胞白血病を引き起こすのか? 臨床血液 62 : 744-750, 2021.
7) 下山正徳 : レトロウイルス疾患ATLおよびHTLV関連疾患. ATL臨床症状症状・病態・合併症・予後因子. 病理と臨床 11 (臨時増刊号) : 132-146, 1993.
8) Kiyokawa T, et al : Hypercalcemia and osteoclast proliferation in adult T-cell leukemia. Cancer 59 : 1187-1191, 1987.
9) Nosaka K, et al : Mechanism of hypercalcemia in adult T-cell leukemia : overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells. Blood 99 : 634-640, 2002.
10) Shu ST, et al : Osteolytic bone resorption in adult T-cell leukemia/lymphoma. Leuk Lymphoma 51 : 702-714, 2010.
11) Xiang J, et al : HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia. JCI insight 4 : e128713, 2019.
12) Kohart NA, et al : Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors. Leuk Lymphoma 61 : 409-419, 2020.
13) Nadella MV, et al : Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-κB in adult T-cell leukemia/lymphoma. Leukemia 21 : 1752-1762, 2007.
14) 高橋秀明, ほか : 副甲状腺ホルモン関連蛋白質高値を示し, 著明な高Ca血症と急性腎不全を合併した成人T細胞白血病の1症例. 臨床体液 36 : 25-28, 2009.
15) 造血器腫瘍診療ガイドライン [2018年版] (日本血液学会編), 金原出版, 2018.
P.129 掲載の参考文献
1) Rajkumar SV, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-548, 2014.
2) Sathick IJ, et al : Myeloma light chain cast nephropathy, a review. J Nephrol 32 : 189-198, 2019.
3) Dimopoulos MA, et al : Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25 : 195-200, 2014.
5) Kundu S, et al : Multiple Myeloma and Renal Failure : Mechanisms, Diagnosis, and Management. Cureus 14 : e22585, 2022.
6) Solomon A, et al : Nephrotoxic potential of Bence Jones proteins. N Engl J Med 324 : 1845-1851, 1991.
7) Ozsan GH, Dispenzieri A : Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias. Expert Rev Clin Immunol 7 : 65-73, 2011.
9) Kumar S, Muchmore A : Tamm-Horsfall protein-uromodulin (1950-1990). Kidney Int 37 : 1395-1401, 1990.
10) Ying WZ, Sanders PW : Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 158 : 1859-1866, 2001.
11) Sanders PW, et al : Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 85 : 570-576, 1990.
12) Horton JK, et al : Activation of the inflammatory response of neutrophils by Tamm-Horsfall glycoprotein. Kidney Int 37 : 717-726, 1990.
13) Sanders PW : Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol 23 : 1777-1781, 2012.
14) Preston FE, et al : Myelomatosis and the hyperviscosity syndrome. Br J Haematol 38 : 517-530, 1978.
15) Kwaan HC : Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc 55 : 75-83, 2013.
16) 多発性骨髄腫の診療指針 [第5版] (日本骨髄腫学会編), 文光堂, 2020.
17) Oshima K, et al : Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 67 : 1-5, 2001.
18) Takano J, et al : Late-stage myeloma invades kidney without significant effect on renal function : findings from 53 autopsies in a single institute. Int J Hematol 109 : 147-153, 2019.
19) Yui JC, et al : Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol 91 : E348-352, 2016.
21) Manohar S, et al : Light Chain Cast Nephropathy : Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold. Curr Hematol Malig Rep 13 : 220-226, 2018.
24) Yu X, et al : Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma : a meta-analysis. Int J Clin Pharmacol Ther 53 : 391-397, 2015.
25) Tarragon B, et al : Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma : a systematic review and meta-analysis. Clin Kidney J 14 : 1894-1900, 2021.
27) Bridoux F, et al : Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. J Clin Oncol 38 : 2647-2657, 2020.
28) Ball S, et al : Risk of kidney toxicity with carfilzomib in multiple myeloma : a meta-analysis of randomized controlled trials. Ann Hematol 99 : 1265-1271, 2020.
29) Courant M, et al : Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma : a population-based registry. Nephrol Dial Transplant 36 : 482-490, 2021.
30) Dimopoulos MA, et al : Outcomes of newly diagnosed myeloma patients requiring dialysis : renal recovery, importance of rapid response and survival benefit. Blood Cancer J 7 : e571, 2017.
31) Dimopoulos MA, et al : Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol 91 : 499-502, 2016.
P.135 掲載の参考文献
1) 涌井秀樹 : 多発性骨髄腫と類縁疾患の腎障害. 臨床血液 54 : 1876-1887, 2013.
2) Sethi S, et al : The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol 29 : 1810-1823, 2018.
4) Preud' homme JL, et al : Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 46 : 965-972, 1994.
6) Kourelis TV, et al : Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol 91 : 1123-1128, 2016.
7) Nara M, et al : Long-term prognosis of monoclonal immunoglobulin-associated glomerular diseases with nonorganized deposits : a report of 38 cases from a Japanese single center. Clin Nephrol, 2022. (DOI : 10.5414/CN110865)
9) Joly F, et al : Randall-type monoclonal immunoglobulin deposition disease : novel insights from a nationwide cohort study. Blood 133 : 576-587, 2019.
10) Cohen C, et al : Randall-type monoclonal immunoglobulin deposition disease : new insights into the pathogenesis, diagnosis and management. Diagnostics (Basel) 11 : 420, 2021.
11) Oe Y, et al : Heavy chain deposition disease : an overview. Clin Exp Nephrol 17 : 771-778, 2013.
12) Bridoux F, et al : Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Kidney Int 91 : 423-434, 2017.
14) Lin J, et al : Renal monoclonal immunoglobulin deposition disease : the disease spectrum. J Am Soc Nephrol 12 : 1482-1492, 2001.
15) Cohen C, et al : Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88 : 1135-1143, 2015.
P.140 掲載の参考文献
1) 森茂郎, ほか : 著しい多クローン性高免疫グロブリン血症と全身リンパ節の高度の形質細胞増生を呈する症候群-形質細胞型Castlemanリンパ腫との異同. 日本リンパ網内系学会会誌 20 : 85-94, 1980.
3) 中澤哲也, ほか : Castleman病 ; 各種病態にみられる腎障害. 造血器疾患. 別冊日本臨牀領域別症候群シリーズ No.17 腎臓症候群 (下巻), p288-291, 日本臨牀社, 1997.
4) Frizzera G : Castleman's disease and related disorders. Semin Diagn Pathol 5 : 346-364, 1988.
5) 森茂郎 : 特殊な悪性リンパ腫IPL (特発性形質細胞性リンパ節症). カレントテラピー 9 : 232-234, 1991.
7) Fajgenbaum DC, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017.
8) 正木康史, ほか : 新規疾患-TAFRO症候群の診断基準・重症度分類・治療指針-. 臨床血液 57 : 2029-2037, 2016.
10) キャッスルマン病診療ガイドライン 令和2年度初版 (キャッスルマン病診療ガイドライン統括委員会キャッスルマン病診療ガイドライン作成ワーキンググループ編), 2020.
11) Kawabata H, et al : Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53 : 69-77, 2013.
12) 富山順治 : 特発性形質細胞性リンパ節症 (IPL) に伴う腎病変 ; 各種病態にみられる腎障害. 造血器疾患. 別冊日本臨牀新領域別症候群シリーズ No.18 腎臓症候群 (第2版) 下, p439-443, 日本臨牀社, 2012.
13) 海渡健, 酒井紀 : 特発性形質細胞性リンパ節症 (IPL) に伴う腎病変 ; 各種病態にみられる腎障害. 造血器疾患. 別冊日本臨牀領域別症候群シリーズ No.17 腎臓症候群 (下巻), p343-346, 日本臨牀社, 1997.
14) 坂井晃, 河野道生 : Castleman 病とIPL. 医学のあゆみ 162 : 84-87, 1992.
18) Chan TM, et al : Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease). Nephron 65 : 628-632, 1993.
19) Horii Y, et al : Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 143 : 3949-3955, 1989.
21) 吉崎和幸, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017.
22) Kato Y, et al : Ticlopidine treatment in idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia accompanied by nephrotic syndrome. Intern Med 31 : 504-507, 1992.
24) 柏原亜希子, ほか : 腎不全を契機に診断されたMulticentric Castleman病の1例. 倉敷中央病院年報 73 : 227-231, 2010.
25) Kojima M, et al : Clinical implications of idiopathic multicentric castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008.
P.147 掲載の参考文献
1) Adelborg K, et al : Disseminated intravascular coagulation : epidemiology, biomarkers, and management. Br J Haematol 192 : 803-818, 2021.
2) Matsuda T : Clinical aspects of DIC--disseminated intravascular coagulation. Pol J Pharmacol 48 : 73-75, 1996.
3) 中川雅夫 : 厚生省特定疾患血液系疾患調査研究班血液凝固異常症分科会, 平成10年度研究業績報告書, p57-64, 1999.
4) Gando S, et al : Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients : results of a multicenter, prospective survey. Crit Care Med 36 : 145-150, 2008.
5) 朝倉英策 : 播種性血管内凝固症候群 (DIC). 臨床に直結する血栓止血学 [改訂2版] (朝倉英策編), p286-299, 中外医学社, 2018.
6) DIC診断基準作成委員会 : 日本血栓止血学会DIC診断基準 2017年版. 日本血栓止血学会誌 28 : 369-391, 2017.
7) 山田真也, 朝倉英策 : 播種性血管内凝固. 日本医師会雑誌 151 (特別号 1 : 血液疾患のすべて) : 335-337, 2022.
8) Tang N, et al : Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18 : 844-847, 2020.
9) Asakura H, Ogawa H : COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol 113 : 45-57, 2021.
12) Ito T, et al : Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care 23 : 280, 2019.
13) Yamato M, et al : Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation : a historical controlled trial. Ther Apher Dial 17 : 472-476, 2013.
14) Akatsuka M, et al : The effect of recombinant human soluble thrombomodulin on renal function and mortality in septic disseminated intravascular coagulation patients with acute kidney injury : a retrospective study. J Intensive Care 8 : 94, 2020.
15) Hayakawa M, et al : Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction. Thromb Haemost 117 : 851-859, 2017.
P.150 掲載の参考文献
1) Xiao JC, et al : Renal involvement in myeloproliferative and lymphoproliferative disorders. A study of autopsy cases. Gen Diagn Pathol 142 : 147-153, 1997.
2) Luciano RL, Brewster UC : Kidney involvement in leukemia and lymphoma. Adv Chronic Kidney Dis 21 : 27-35, 2014.
3) Obrador GT, et al : Acute renal failure due to lymphomatous infiltration of the kidneys. J Am Soc Nephrol 8 : 1348-1354, 1997.
4) 酒井謙 : 白血病と腎障害 ; 各種病態にみられる腎障害. 造血器疾患. 別冊日本臨牀新領域別症候群シリーズ No.18 腎臓症候群 (第2版) 下, p448-451, 2012.
5) Lange Textbookシリーズジュンケイラ組織学 第5版 [原書14版] (坂井建雄, 川上速人監訳), 丸善出版, 2018.
6) Santoriello D, et al : Lysozyme-Induced Nephropathy. Kidney Int Rep 2 : 84-88, 2017.
7) Levinson SS, et al : Light chain proteinuria and lysozymuria in a patient with acute monocytic leukemia. Clin Chem 48 : 1131-1132, 2002.
10) Spencer HW, et al : Alterations of renal function during dietary-induced hyperuricemia in the rat. Kidney Int 9 : 489-500, 1976.
12) Sanchez-Lozada LG, et al : Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283 : F1105-1110, 2002.
13) Arnaud M, et al : Tumor Lysis Syndrome and AKI : Beyond Crystal Mechanizms. J Am Soc Nephrol 33 : 1154-1171, 2022.
14) Andronesi A, et al : Incidence and Risk Factors for Acute Kidney Injury after Allogeneic Stem Cell Transplantation : A Prospective Study. Biomedicines 10 : 262, 2022.
15) Ma Q, et al : Kidney Injury in Murine Models of Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 25 : 1920-1924, 2019.
16) Schmid PM, et al : Acute Renal Graft-Versus-Host Disease in a Murine Model of Allogeneic Bone Marrow Transplantation. Cell Transplant 26 : 1428-1440, 2017.
17) Beyar-Katz O, et al : Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation : Renal Pathology is the Best Predictor of Response to Therapy. Biol Blood Marrow Transplant 22 : 975-981, 2016.
18) Huang X, et al : Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy. Am J Med Sci 346 : 32-37, 2013.
19) エビデンスに基づくネフローゼ症候群診療ガイドライン 2020 (成田一衛監/厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎障害に関する調査研究班編), 東京医学社, 2020.
P.156 掲載の参考文献
1) Nishimura JI, et al : Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83 : 193-207, 2004.
3) Villegas A, et al : Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria : results of a retrospective analysis from the Spanish PNH Registry. Ann Hematol 96 : 1727-1733, 2017.
4) Fureder W, et al : Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH) : experience of the Austrian PNH network. Ann Hematol 99 : 2303-2313, 2020.
5) Ninomiya H, et al : Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol 104 : 548-558, 2016.
6) Kokoris SI, et al : Renal involvement in paroxysmal nocturnal hemoglobinuria : an update on clinical features, pathophysiology and treatment. Hematology 23 : 558-566, 2018.
7) Zager RA, Gamelin LM : Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am J Physiol 256 (3 Pt 2) : F446-F455, 1989.
8) Ballarin J, et al : Acute renal failure associated to paroxysmal nocturnal haemoglobinuria leads to intratubular haemosiderin accumulation and CD163 expression. Nephrol Dial Transplant 26 : 3408-3411, 2011.
9) Peacock-Young B, et al : The prothrombotic state in paroxysmal nocturnal hemoglobinuria : a multifaceted source. Haematologica 103 : 9-17, 2018.
10) Schubert J, Roth A : Update on paroxysmal nocturnal haemoglobinuria : on the long way to understand the principles of the disease. Eur J Haematol 94 : 464-473, 2015.
11) Hsiao PJ, et al : Fanconi syndrome and CKD in a patient with paroxysmal nocturnal hemoglobinuria and hemosiderosis. Am J Kidney Dis 55 : e1-5, 2010.
12) Iki S, et al : Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria. Int J Hematol 105 : 231-232, 2017.
14) Hillmen P, et al : Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162 : 62-73, 2013.
15) Sampei Z, et al : Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS One 13 : e0209509, 2018.
P.161 掲載の参考文献
1) 香美祥二, ほか ; 非典型溶血性尿毒症症候群診断基準作成委員会 : 非典型溶血性尿毒症症候群診断基準. 日本腎臓学会誌 55 : 91-93, 2013.
2) 香美祥二, ほか ; 非典型溶血性尿毒症症候群診断基準改訂委員会 : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015. 日本腎臓学会誌 58 : 62-75, 2016.
3) 松本雅則, ほか ; 難治性疾患等政策研究事業「血液凝固異常症に関する調査研究班」TTPグループ : 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2017. 臨床血液 58 : 271-281, 2017.
4) 国立感染症研究所 : 病原微生物検出情報. [https://www.niid.go.jp/niid/ja/iasr.html]
5) 伊豫田淳 : 腸管出血性大腸菌感染症. 日本臨牀 79 : 200-204, 2021.
6) Joseph A, et al : Shiga Toxin-Associated Hemolytic Uremic Syndrome : A Narrative Review. Toxins (Basel) 12 : 67, 2020.
7) Feng P, et al : Genotypic and phenotypic changes in the emergence of Escherichia coli O157 : H7. J Infect Dis 177 : 1750-1753, 1998.
8) Gould LH, et al : Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010 : epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis 10 : 453-460, 2013.
9) Frank C, et al : Epidemic profile of Shiga-toxin-producing Escherichia coli O104 : H4 outbreak in Germany. N Engl J Med 365 : 1771-1780, 2011.
10) Shimizu M : Pathogenic functions and diagnostic utility of cytokines/chemokines in EHECHUS. Pediatr Int 62 : 308-315, 2020.
11) Blasco M, et al : Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Front Med (Lausanne) 9 : 811504, 2022.
P.165 掲載の参考文献
1) Kyle RA, et al : Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 378 : 241-249, 2018.
3) Sethi S, et al : The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases. J Am Soc Nephrol 29 : 1810-1823, 2018.
4) Ying WZ, et al : Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest 122 : 1777-1785, 2012.
5) 水野真一 : 多発性骨髄腫の腎病変とMGRS. 日本内科学会雑誌 105 : 1224-1230, 2016.
6) Herrera GA : Proximal tubulopathies associated with monoclonal light chains : the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch Pathol Lab Med 138 : 1365-1380, 2014.
7) Stokes MB, et al : Light Chain Proximal Tubulopathy : Clinical and Pathologic Characteristics in the Modern Treatment Era. J Am Soc Nephrol 27 : 1555-1565, 2016.
8) Vignon M, et al : Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome : a retrospective series of 49 patients. Leukemia 31 : 123-129, 2017.
P.170 掲載の参考文献
1) ANCA関連血管炎診療ガイドライン 2017 (厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究班 : 有村義宏, ほか編), 診断と治療社, 2017.
2) エビデンスに基づく急速進行性腎炎症候群 (RPGN) 診療ガイドライン 2020 (成田一衛監, 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「難治性腎障害に関する調査研究」班編), 東京医学社, 2020.
3) 難病情報センター : 特定医療費 (指定難病) 受給者証所持者数. [https://www.nanbyou.or.jp/entry/5354]
7) Tsuchiya N, et al : Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis : association of HLA-DRB1*0901 with microscopic polyangiitis. J Rheumatol 30 : 1534-1540, 2003.
8) Esnault VL, et al : Alpha-1-antitrypsin phenotyping in ANCA-associated diseases : one of several arguments for protease/antiprotease imbalance in systemic vasculitis. Exp Clin Immunogenet 14 : 206-213, 1997.
10) Lyons PA, et al : Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10 : 5120, 2019.
11) Popa ER, et al : Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 4 : 77-79, 2002.
13) Kawashima S, et al : Immunopathologic co-localization of MPO, IgG, and C3 in glomeruli in human MPO-ANCA-associated glomerulonephritis. Clin Nephrol 79 : 292-301, 2013.
14) Xiao H, et al : C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25 : 225-231, 2014.
15) 有村義宏, ほか : ANCA関連血管炎とRPGN. 日本腎臓学会誌 51 : 88-93, 2009.
P.175 掲載の参考文献
1) Akpolat T, et al : Renal Behcet's disease : an update. Semin Arthritis Rheum 38 : 241-248, 2008.
4) Takeuchi M, et al : Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet's disease susceptibility. Nat Genet 49 : 438-443, 2017.
5) Hashimoto T, et al : Behcet's disease complicated by IgA nephropathy with nephrotic syndrome. Clin Exp Nephrol 12 : 224-227, 2008.
7) Leonard D, et al : Behcet's syndrome and focal segmental glomerulosclerosis with nephrotic syndrome-successful treatment with etanercept. Clin Nephrol 89 : 371-375, 2018.
8) Ueno Y, et al : Infliximab treatment for Crohn's disease in a patient with IgA nephropathy. Clin J Gastroenterol 2 : 380-383, 2009.
9) Chessa E, et al : Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases : An Updated Systematic Literature Review. BioDrugs 35 : 175-186, 2021.
10) Watanabe-Kusunoki K, et al : Parallel desease activity of Behcet's disease with renal and entero involvements : a case report. BMC Nephrol 22 : 126, 2021.
11) Redondo-Pachon MD, et al : Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease. Ren Fail 35 : 547-550, 2013.
13) Belmouaz S, et al : Tubulo-interstitial nephritis with Fanconi syndrome in Behcet disease. Nephrol Dial Transplant 22 : 2079-2083, 2007.
14) Akpolat T, et al : Behcet's disease and renal failure. Nephrol Dial Trans 18 : 888-891, 2003.
15) Ponticelli C, et al : Recurrence of secondary glomerular disease after renal transplantation. Clin J Am Soc Nephrol 6 : 1214-1221, 2011.
P.181 掲載の参考文献
1) 天野宏一 : アレルギー性肉芽腫性血管炎/Churg-Strauss syndrome. リウマチ科 45 : 386-392, 2011.
2) Mouthon L, et al : Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun 48-49 : 99-103, 2014.
5) Sable-Fourtassou R, et al : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143 : 632-638, 2005.
7) Lyons PA, et al : Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10 : 5120, 2019.
8) Saku A, et al : Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis. J Rheumatol 45 : 1159-1166, 2018.
10) Kronbichler A, et al : Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev 19 : 102495, 2020.
11) Durel CA, et al : Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA) : a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology (Oxford) 60 : 359-365, 2021.
12) Grayson PC, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol 74 : 386-392, 2022.
13) 抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究 ; 針谷正祥編), p39-50, 診断と治療社, 2021.
14) Wechsler ME, et al : Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 376 : 1921-1932, 2017.
15) Menditto VG, et al : Rituximab for eosinophilic granulomatosis with polyangiitis : a systematic review of observational studies. Rheumatology (Oxford) 60 : 1640-1650, 2021.
16) Terrier B, et al : Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis : A Double-blind, Randomized, Controlled Trial. Meeting : ACR Convergence 2021, Late-Braking Abstract (L21), American Colledge of Rheumatology, 2021.
P.187 掲載の参考文献
2) Ramos-Casals M, et al : Characterization of systemic disease in primary Sjogren's syndrome : EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 54 : 2230-2238, 2015.
3) Goules AV, et al : Clinically significant renal involvement in primary Sjogren's syndrome : clinical presentation and outcome. Arthritis Rheum 65 : 2945-2953, 2013.
4) Goules A, et al : Renal involvement in primary Sjogren's syndrome : natural history and treatment outcome. Clin Exp Rheumatol 37 (Suppl 118) : 123-132, 2019.
5) Jain A, et al : Renal involvement in primary Sjogren's syndrome : a prospective cohort study. Rheumatol Int 38 : 2251-2262, 2018.
6) Mariette X, Criswell LA : Primary Sjogren's Syndrome. N Engl J Med 378 : 931-939, 2018.
7) Manuel RC, et al : Characterization of systemic disease in primary Sjogren's syndrome : EULARSS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 56 : 1245, 2017.
8) Francois H, Mariette X : Renal involvement in primary Sjogren syndrome. Nat Rev Nephrol 12 : 82-93, 2016.
9) Jasiek M, et al : A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjogren's syndrome. Rheumatology (Oxford) 56 : 362-370, 2017.
11) Evans R, et al : Renal involvement in primary Sjogren's syndrome. Rheumatology (Oxford) 54 : 1541-1548, 2015.
12) Cohen EP, et al : Absence of H (+) -ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal tubular acidosis. J Am Soc Nephrol 3 : 264-271, 1992.
14) Brito-Zeron P, et al : Efficacy and safety of topical and systemic medications : a systematic literature review informing the EULAR recommendations for the management of Sjogren's syndrome. RMD Open 5 : e001064, 2019.
15) Ramos-Casals M, et al : EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis 79 : 3-18, 2020.
P.192 掲載の参考文献
1) Asanuma YF, et al : Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol 25 : 393-400, 2015.
2) Maruyama A, et al : Usefulness of the severity classification for predicting drug-free remission in Japanese patients with adult-onset Still's disease. Mod Rheumatol, 2021. (DOI : 10.1093/mr/roab083)
3) Sugiyama T, et al : Latent class analysis of 216 patients with adult-onset Still's disease. Arthritis Res Ther 24 : 7, 2022.
4) Feist E, et al : Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol 14 : 603-618, 2018.
5) Masuyama A, et al : A case of adult-onset Still's disease complicated by thrombotic thrombocytopenic purpura with retinal microangiopathy and rapidly fatal cerebral edema. Mod Rheumatol 23 : 379-385, 2013.
6) Sumida K, et al : Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 29 : 1191-1194, 2010.
7) Khattab A, et al : Aggressive Disease and Rare Sequelae in a Unique Case of Atypical Hemolytic Uremic Syndrome Secondary to Adult Onset Still's Disease. J Hematol 8 : 64-67, 2019.
8) Neel A, et al : Diagnostic and management of life-threatening Adult-Onset Still Disease : a French nationwide multicenter study and systematic literature review. Crit Care 22 : 88, 2018.
9) Minoia F, et al : Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome : A Multinational Study of 23 Patients. J Pediatr 235 : 196-202, 2021.
10) Kumar S, et al : Collapsing glomerulopathy in adult still's disease. Am J Kidney Dis 43 : e4-10, 2004.
11) Bennett AN, et al : Adult onset Still's disease and collapsing glomerulopathy : successful treatment with intravenous immunoglobulins and mycophenolate mofetil. Rheumatology (Oxford) 43 : 795-799, 2004.
12) Mezouar IE, et al : An unusual manifestation in a patient with adult-onset Still's disease : Minimal glomerular lesion. Eur J Rheumatol 1 : 123-124, 2014.
13) Delplanque M, et al : AA amyloidosis secondary to adult onset Still's disease : About 19 cases. Semin Arthritis Rheum 50 : 156-165, 2020.
P.196 掲載の参考文献
3) Fujimoto S, et al : Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 50 : 1916-1920, 2011.
7) Robson JC, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 81 : 315-320, 2022.
10) Jayne DRW, et al : Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 384 : 599-609, 2021.
P.202 掲載の参考文献
1) Koseki Y, et al : A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis 60 : 327-331, 2001.
3) Saisho K, et al : Prevalence of chronic kidney disease and administration of RA-related drugs in patients with RA : The NinJa 2012 study in Japan. Mod Rheumatol 26 : 331-335, 2016.
4) Tokoroyama T, et al : Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines : a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant 32 : 2035-2042, 2017.
5) Mori S, et al : Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients : a cross-sectional study in community hospitals. Clin Rheumatol 36 : 2673-2682, 2017.
7) Piga M, et al : Demyelinating syndrome in SLE encompasses different subtypes : Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev 16 : 244-252, 2017.
8) Chessa E, et al : Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases : An Updated Systematic Literature Review. BioDrugs 35 : 175-186, 2021.
9) Fukaya D, et al : Tocilizumab-induced immunocomplex glomerulonephritis : a report of two cases. CEN Case Rep 9 : 318-325, 2020.
10) Hansrivijit P, et al : Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease : A systematic review of case reports, case series, and observational studies. Clin Nephrol 94 : 117-126, 2020.
11) Sawamura M, et al : Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis : a retrospective analysis. Clin Exp Nephrol 26 : 341-349, 2022.
12) Kochi M, et al : Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLoS One 11 : e0160225, 2016.
13) Onishi A, et al : The Association of Disease Activity and Estimated GFR in Patients With Rheumatoid Arthritis : Findings From the ANSWER Study. Am J Kidney Dis 78 : 761-764, 2021.
14) Sumida K, et al : Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int 93 : 1207-1216, 2018.
15) Hanaoka H, et al : Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. Clin Kidney J 15 : 1373-1378, 2022.
P.206 掲載の参考文献
1) Hao Y, et al : Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis Rheumatol 69 : 1067-1077, 2017.
3) Matucci-Cerinic M, et al : The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 68 : 1377-1380, 2009.
4) Shanmugam VK, Steen VD : Renal disease in scleroderma : an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 24 : 669-676, 2012.
5) Kingdon EJ, et al : Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology (Oxford) 42 : 26-33, 2003.
6) Lin CY, et al : Increased risk of end-stage renal disease in patients with systemic sclerosis. Scand J Rheumatol 51 : 120-127, 2022.
7) Kuwana M, et al : Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan : Analysis Using Japanese Claims Databases. Adv Ther 39 : 2222-2235, 2022.
9) Walker UA, et al : Clinical risk assessment of organ manifestations in systemic sclerosis : a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66 : 754-763, 2007.
11) Sobanski V, et al : Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis : New data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 66 : 407-417, 2014.
12) Butikofer L, et al : ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. Arthritis Res Ther 22 : 59, 2020.
13) Lynch BM, et al : UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol 34 (Suppl 100) : 106-109, 2016.
14) Montrief T, et al : Scleroderma renal crisis : a review for emergency physicians. Intern Emerg Med 14 : 561-570, 2019.
16) Guillevin L, et al : Scleroderma renal crisis : a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 51 : 460-467, 2012.
P.211 掲載の参考文献
3) 中林公正, 橋本博史 : 結節性多発動脈炎. 難治性血管炎の診療マニュアル (厚生科学研究特定疾患対策研究事業難治性血管炎に関する調査研究班編), p19-23, 2002.
5) Kawazoe M, et al : Clinical characteristics of patients with polyarteritis nodosa based on a nationwide database in Japan. Mod Rheumatol 32 : 598-605, 2022.
7) Schnappauf O, et al : Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis Rheumatol 73 : 512-519, 2021.
8) Yokota K, et al : Acute kidney injury in a patient with polyarteritis nodosa and multiple myeloma. Intern Med 53 : 263-267, 2014.
9) Chung SA, et al : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care Res (Hoboken) 73 : 1061-1070, 2021.
10) 血管炎症候群の診療ガイドライン (2017年改訂版) (日本循環器学会, ほか), p53-54, 2018.
P.217 掲載の参考文献
2) ANCA関連血管炎診療ガイドライン 2017 (厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究班 ; 有村義宏, ほか編), p48-143, 診断と治療社, 2017.
3) Kawasaki A, et al : Protective Role of HLA-DRB1*13 : 02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population : A Case-Control Study. PLoS One 11 : e0154393, 2016.
6) Kallenberg CG : Pathogenesis and treatment of ANCA-associated vasculitides. Clin Exp Rheumatol 33 : S11-14, 2015.
8) Sethi S, et al : Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis : results of a proteomic analysis. Nephrol Dial Transplant 32 : i139-i145, 2017.
9) Kojima T, et al : Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis. Ren Fail 44 : 714-723, 2022.
10) Jayne DRW, et al : Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 384 : 599-609, 2021.
11) Jones BE, et al : ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation. Kidney Int 98 : 744-757, 2020.
12) Yoshida M, et al : Neutrophil extracellular trap components in fibrinoid necrosis of the kidney with myeloperoxidase-ANCA-associated vasculitis. Clin Kidney J 6 : 308-312, 2013.
13) Suppiah R, et al : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 81 : 321-326, 2022.
15) Yamagata K, et al : Temporal change in life and renal prognosis of rapidly progressive glomerulonephritis in Japan via nationwide questionnaire survey. Clin Exp Nephrol 23 : 573-575, 2019.
P.222 掲載の参考文献
1) Cervera R, et al : Antiphospholipid syndrome : clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 : 1019-1027, 2002.
2) Nochy D, et al : The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10 : 507-518, 1999.
3) Fakhouri F, et al : The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 41 : 1205-1211, 2003.
4) Alchi B, et al : What nephrologists need to know about antiphospholipid syndrome. Nephrol Dial Transplant 25 : 3147-3154, 2010.
5) Daugas E, et al : Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13 : 42-52, 2002.
6) Jordan N, et al : Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. Arthritis Care Res (Hoboken) 66 : 725-731, 2014.
7) Cervera R, et al : Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64 : 1205-1209, 2005.
8) Ostuni PA, et al : Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis 49 : 184-187, 1990.
9) Sciascia S, et al : Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol 10 : 279-289, 2014.
10) Girometti R, et al : Impact of contrast-enhanced ultrasound in patients with renal function impairment. World J Radiol 9 : 10-16, 2017.
12) Ko WS, et al : Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome. Nephrol Dial Transplant 10 : 1929-1931, 1995.
13) Sinico RA, et al : Renal involvement in primary antiphospholipid syndrome : retrospective analysis of 160 patients. Clin J Am Soc Nephrol 5 : 1211-1217, 2010.
14) Tektonidou MG : Antiphospholipid syndrome nephropathy : from pathogenesis to treatment. Front Immunol 9 : 1181, 2018.
15) Tektonidou MG, et al : EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78 : 1296-1304, 2019.
17) 抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 難治性血管炎に関する調査研究 : 針谷正祥編), p44-65, 診断と治療社, 2021.
18) Pengo V, et al : Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132 : 1365-1371, 2018.
19) Oku K, et al : How to Identify High-Risk APS Patients : Clinical Utility and Predictive Values of Validated Scores. Curr Rheumatol Rep 19 : 51, 2017.
20) Tektonidou MG : Identification and treatment of APS renal involvement. Lupus 23 : 1276-1278, 2014.
21) Seshan SV, et al : Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 114 : 1675-1683, 2009.
24) Erkan D, et al : A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65 : 464-471, 2013.
25) Romay-Penabad Z, et al : Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 23 : 1324-1326, 2014.
26) Sciascia S, et al : Expanding the therapeutic options for renal involvement in lupus : eculizumab, available evidence. Rheumatol Int 37 : 1249-1255, 2017.
27) Guillot M, et al : Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review. Rheumatology (Oxford) 57 : 2055-2057, 2018.
28) Canaud G, et al : Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 371 : 303-312, 2014.
29) Kazzaz NM, et al : Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol 28 : 218-227, 2016.
30) Isenberg DA, et al : Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus. Ann Rheum Dis 41 : 347-351, 1982.
31) Bucciarelli S, et al : Mortality in the catastrophic antiphospholipid syndrome : causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54 : 2568-2576, 2006.
32) Asherson RA : The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 7 (Suppl 2) : S55-62, 1998.
33) Bayraktar UD, et al : The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 34 : 346-352, 2007.
34) Berman H, et al : Rituximab use in the catastrophic antiphospholipid syndrome : descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12 : 1085-1090, 2013.
35) Zikos TA, et al : Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. J Clin Rheumatol 21 : 311-313, 2015.
36) Garcia-Martin F, et al : Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 6 : 543-547, 1991.
37) Fastenau DR, et al : Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients. Ann Thorac Surg 68 : 137-142, 1999.
38) Prieto LN, Suki WN : Frequent hemodialysis graft thrombosis : association with antiphospholipid antibodies. Am J Kidney Dis 23 : 587-590, 1994.
39) Stone JH, et al : Antiphospholipid antibody syndrome in renal transplantation : occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 34 : 1040-1047, 1999.
40) Wagenknecht DR, et al : Antiphospholipid antibodies are a risk factor for early renal allograft failure : isolation of antiphospholipid antibodies from a thrombosed renal allograft. Transplant Proc 31 : 285-288, 1999.
41) Canaud G, et al : Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 10 : 2051-2060, 2010.
42) Gauthier M, et al : Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients : a prognosis cohort survey. Nephrol Dial Transplant 33 : 709-716, 2018.
P.227 掲載の参考文献
2) MCTD (混合性結合組織病) 診療ガイドライン 2021 (厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 自己免疫疾患研究班混合性結合組織病分科会編), 南山堂, 2021.
3) Gutierrez MJB, et al : Mixed connective tissue disease (MCTD) : 6 case based review. J Musculoskelet Disord Treat 6 : 080, 2020.
4) Chaigne B, et al : Mixed connective tissue disease : state of the art on clinical practice guidelines. RMD Open 4 (Suppl 1) : e000783, 2018.
P.230 掲載の参考文献
2) Komatsu H, et al : Clinical manifestations of Henoch-Schonlein purpura nephritis and IgA nephropathy : comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 20 : 552-560, 2016.
4) Gonzalez-Gay MA, et al : IgA Vasculitis : Genetics and Clinical and Therapeutic Management. Curr Rheumatol Rep 20 : 24, 2018.
5) 難病情報センター : 紫斑病性腎炎 (指定難病224). [https://www.nanbyou.or.jp/entry/4658]
6) Komatsu H, et al : Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schonlein purpura) with nephritis : Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR). PLoS One 13 : e0196955, 2018.
7) Pillebout E : [Adult Henoch-Schonlein purpura]. Presse Med 37 : 1773-1778, 2008.
9) Kang Y, et al : Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schonlein purpura. J Korean Med Sci 29 : 198-203, 2014.
10) Chan H, et al : Risk Factors Associated with Renal Involvement in Childhood Henoch-Schonlein Purpura : A Meta-Analysis. PLoS One 11 : e0167346, 2016.
11) Hocevar A, et al : IgA vasculitis in adults : the performance of the EULAR/PRINTO/PRES classification criteria in adults. Arthritis Res Ther 18 : 58, 2016.
12) 日本皮膚科学血管炎・血管障害診療ガイドライン改訂版作成委員会 ; 古川福美, ほか : 血管炎・血管障害診療ガイドライン 2016年改訂版. 日本皮膚科学会雑誌 127 : 299-415, 2017.
13) 血管炎症候群の診療ガイドライン (2017年改訂版) (厚生労働省難治性疾患政策研究事業難治性血管炎に関する調査研究班 ; 磯部光章, ほか), p78-86, 2018.
14) Maritati F, et al : Brief Report : Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schonlein). Arthritis Rheumatol 70 : 109-114, 2018.
P.234 掲載の参考文献
1) Iaccarino L, et al : Overlap connective tissue disease syndromes. Autoimmun Rev 12 : 363-373, 2013.
2) Graf J : Overlap syndromes. In : Firestein & Kelley's Textbook of Rheumatology, 11th ed (ed by Firestein GS, et al), p1569-1583, Elsevier, Philadelphia, 2021.
3) Mosca M, et al : Undifferentiated connective tissue diseases (UCTD) : A review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17 : 615-620, 1999.
4) Cervera R, et al : 'Overlap' syndromes. Ann Rheum Dis 49 : 947-948, 1990.
5) Alharbi S, et al : Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome. J Rheumatol 45 : 1406-1410, 2018.
6) Rodriguez-Reyna TS, Alarcon-Segovia D : Overlap syndromes in the context of shared autoimmunity. Autoimmunity 38 : 219-223, 2005.
7) Koschik RW, et al : Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30 : S12-16, 2012.
8) Pakozdi A, et al : Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 38 : 2406-2409, 2011.
9) Reichlin M, et al : Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 4 : 40-44, 1984.
10) Mosca M, et al : The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun 48-49 : 50-52, 2014.
11) Xie X, et al : Scleroderma-associated thrombotic microangiopathy in overlap syndrome of systemic sclerosis and systemic lupus erythematosus : A case report and literature review. Medicine (Baltimore) 99 : e22582, 2020.
12) Matsuyama T, et al : Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 102 : 371-378, 2009.
13) Wang Y, et al : Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody : A Retrospective Study. Medicine (Baltimore) 95 : e2580, 2016.
14) Turkcapar N, et al : A case of overlap syndrome with rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and secondary Sjogren's syndrome. Rheumatol Int 26 : 841-845, 2006.
P.242 掲載の参考文献
1) Rahman A, Isenberg DA : Systemic lupus erythematosus. N Engl J Med 358 : 929-939, 2008.
2) Silverman E, Eddy A : Systemic lupus erythematosus. In : Textbook of Pediatric Rheumatology, 6th ed (ed by Cassidy JT, et al), p315-343, Elsevier Saunders, Philadelphia, 2011.
4) Aringer M, et al : 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71 : 1400-1412, 2019.
5) van Vollenhoven RF, et al : Treat-to-target in systemic lupus erythematosus : recommendations from an international task force. Ann Rheum Dis 73 : 958-967, 2014.
6) Fanouriakis A, et al : 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78 : 736-745, 2019.
7) Japan college of Rheumatology. Guideline for the management of systemic lupus erythematosus 2019 [Article in Japanese], Nansando, 2019.
8) Kidney Disease : Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100 : S1-S276, 2021.
10) Dall' Era M, et al : Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies. Lupus 28 : 591-596, 2019.
11) Bartels-Peculis L, et al : Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population. Open Access Rheumatol 12 : 117-124, 2020.
12) Furie R, et al : Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 383 : 1117-1128, 2020.
13) Cassia M, et al : Lupus nephritis and B-cell targeting therapy. Expert Rev Clin Immunol 13 : 951-962, 2017.
14) Chen YE, et al : Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3 : 46-53, 2008.
P.247 掲載の参考文献
1) Mizoguchi F, et al : A case of dermatomyositis with rhabdomyolysis, rescued by intravenous immunoglobulin. Mod Rheumatol 25 : 646-648, 2015.
3) Couvrat-Desvergnes G, et al : The spectrum of renal involvement in patients with inflammatory myopathies. Medicine (Baltimore) 93 : 33-41, 2014.
P.252 掲載の参考文献
2) 高安動脈炎. 血管炎症候群の診療ガイドライン (2017年改訂版) (厚生労働省難治性疾患政策研究事業難治性血管炎に関する調査研究班), p9-28, 2018.
3) 高安動脈炎. 2022年改訂版末梢動脈疾患ガイドライン (日本循環器学会/日本血管外科学会合同ガイドライン), p96-100, 2022.
5) Numano F, Kakuta T : Takayasu arteritis-five doctors in the history of Takayasu arteritis. Int J Cardiol 54 (Suppl) : S1-10, 1996.
6) Kato Y, et al : Vessel Wall Inflammation of Takayasu Arteritis Detected by Contrast-Enhanced Magnetic Resonance Imaging : Association with Disease Distribution and Activity. PLoS One 10 : e0145855, 2015.
7) Isobe M, et al : Evaluation of tocilizumab for intractable Takayasu arteritis and 18F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment. J Cardiol 77 : 539-544, 2021.
8) 長澤俊彦 : 血管炎症候群と腎障害. 日本腎臓学会誌 36 : 81-88, 1994.
9) Maritati F, et al : Kidney involvement in medium- and large-vessel vasculitis. J Nephrol 29 : 495-505, 2016.
10) Ito N, et al : Coexistence of IgA nephropathy and renal artery stenosis in Takayasu arteritis : case report and literature review. Rheumatol Int, 2022. (DOI : 10.1007/s00296-021-05066-0)
11) Tiryaki O, et al : Takayasu arteritis : association with focal segmental glomerulosclerosis. Clin Rheumatol 26 : 609-611, 2007.
12) Enos D, et al : Takayasu's arteritis and secondary membranous nephropathy : an exceptional association. BMJ Case Rep 14 : e237945, 2021.
13) Kuroda T, et al : A case of Takayasu arteritis complicated with glomerulonephropathy mimicking membranoproliferative glomerulonephritis : a case report and review of the literature. Rheumatol Int 27 : 103-107, 2006.
14) Kitazawa K, et al : A case of lupus nephritis coexisting with podocytic infolding associated with Takayasu's arteritis. Clin Exp Nephrol 12 : 462-466, 2008.
15) Derbel A, et al : An Unusual Association : Takayasu's Arteritis and Tubulointerstitial Nephritis and Uveitis Syndrome. Eur J Case Rep Intern Med 7 : 002040, 2020.
P.257 掲載の参考文献
2) Ambruzs JM, Larsen CP : Renal Manifestations of Inflammatory Bowel Disease. Rheum Dis Clin North Am 44 : 699-714, 2018.
3) van Hoeve K, Hoffman I : Renal manifestations in inflammatory bowel disease : a systematic review. J Gastroenterol 57 : 619-629, 2022.
4) Dimke H, et al : Risk of Urolithiasis in Patients With Inflammatory Bowel Disease : A Nationwide Danish Cohort Study 1977-2018. Clin Gastroenterol Hepatol 19 : 2532-2540.e2, 2021.
5) Joher N, et al : Immunoglobulin A nephropathy in association with inflammatory bowel diseases : results from a national study and systematic literature review. Nephrol Dial Transplant 37 : 531-539, 2022.
7) Archimandritis AJ, Weetch MS : Kidney granuloma in Crohn's disease. BMJ 307 : 540-541, 1993.
8) Tokuyama H, et al : Acute interstitial nephritis associated with ulcerative colitis. Clin Exp Nephrol 14 : 483-486, 2010.
9) Pedersen N, et al : Risk of extra-intestinal cancer in inflammatory bowel disease : meta-analysis of population-based cohort studies. Am J Gastroenterol 105 : 1480-1487, 2010.
12) World MJ, et al : Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 11 : 614-621, 1996.
14) Feng D, et al : Risk of renal cancer in patients with inflammatory bowel disease : A pooled analysis of population-based studies. Urol Oncol 39 : 93-99, 2021.
15) Park S, et al : Increased end-stage renal disease risk in patients with inflammatory bowel disease : A nationwide population-based study. World J Gastroenterol 24 : 4798-4808, 2018.
P.261 掲載の参考文献
1) Arroyo V, et al : Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23 : 164-176, 1996.
3) Gines P, et al : Hepatorenal syndrome. Nat Rev Dis Primers 4 : 23, 2018.
4) Boyer TD, et al : Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 17 : 1328-1332, 2011.
6) Angeli P, et al : Diagnosis and management of acute kidney injury in patients with cirrhosis : revised consensus recommendations of the International Club of Ascites. J Hepatol 62 : 968-974, 2015.
7) European Association for the Study of the Liver. Electronic address : easloffice@easloffice.eu, et al : EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69 : 406-460, 2018.
8) Ghosh S, et al : Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome : a randomized pilot study. Liver Int 33 : 1187-1193, 2013.
9) Song T, et al : Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome : A systematic review and meta-analysis. Dig Liver Dis 50 : 323-330, 2018.
10) Okamura Y, et al : Influence of hepatorenal syndrome on outcome of living donor liver transplantation : A single-center experience in 357 patients. Hepatol Res 47 : 425-434, 2017.
P.267 掲載の参考文献
1) Rubin E, et al : Primary Biliary Cirrhosis. Chronic Non-Suppurative Destructive Cholangitis. Am J Pathol 46 : 387-407, 1965.
2) 厚生労働省難治性疾患克服研究事業「難治性の肝・胆道疾患に関する調査研究」班, 2013.
3) Worman HJ : Nuclear envelope protein autoantigens in primary biliary cirrhosis. Hepatol Res 37 (Suppl 3) : S406-411, 2007.
4) Metcalf JV, et al : Natural history of early primary biliary cirrhosis. Lancet 348 : 1399-1402, 1996.
6) 原発性胆汁性胆管炎 (PBC) 診療ガイドライン (2017年) (厚生労働省難治性疾患克服研究事業「難治性の肝・胆道疾患に関する調査研究」班編), 2017.
7) Arora A, et al : INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. J Clin Exp Hepatol 11 : 354-386, 2021.
9) Kuiper EM, et al : Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136 : 1281-1287, 2009.
11) Gong Y, et al : Ursodeoxycholic acid for patients with primary biliary cirrhosis : an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 102 : 1799-1807, 2007.
12) Itakura J, et al : Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 29 : 216-222, 2004.
13) Rishe E, et al : Itch in primary biliary cirrhosis : a patients' perspective. Acta Derm Venereol 88 : 34-37, 2008.
14) Guanabens N, et al : Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 138 : 2348-2356, 2010.
15) Mavragani CP, Moutsopoulos HM : Conventional therapy of Sjogren's syndrome. Clin Rev Allergy Immunol 32 : 284-291, 2007.
P.271 掲載の参考文献
1) Tanaka A, et al : Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res 49 : 881-889, 2019.
2) de Boer YS, et al : Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147 : 443-452.e5, 2014.
3) Wei Y, et al : Alterations of gut microbiome in autoimmune hepatitis. Gut 69 : 569-577, 2020.
4) Kerkar N, et al : Cytochrome P4502D6193-212 : a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170 : 1481-1489, 2003.
5) Weiler-Normann C, Schramm C : Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 55 : 747-749, 2011.
6) 大藤和也, ほか : 自己免疫性肝炎の発症機序 (遺伝要因・環境要因, 免疫バランス破綻). 日本臨牀 78 : 58-64, 2020.
7) 高梨訓博 : 自己免疫性肝疾患. 臨床化学 49 : 90-95, 2020.
8) 自己免疫性肝炎 (AIH) 診療ガイドライン (2016年) Ver 3 (厚生労働省難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班編), 2020.
9) 八木みなみ, 田中篤 : 自己免疫性肝炎. 新薬と臨牀 69 : 556-560, 2020.
10) Takahashi A, et al : Autoimmune hepatitis in Japan : trends in a nationwide survey. J Gastroenterol 52 : 631-640, 2017.
11) Yoshizawa K, et al : Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 56 : 668-676, 2012.
12) Czaja AJ : Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 29 : 816-823, 2009.
P.274 掲載の参考文献
1) Patel J, et al : Bile cast nephropathy : A case report and review of the literature. World J Gastroenterol 22 : 6328-6334, 2016.
2) van Slambrouck CM, et al : Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int 84 : 192-197, 2013.
3) 日本消化器学会, 日本肝臓学会 : 肝硬変診療ガイドライン 2020 (改訂第3版), 南江堂, 2020.
4) Adebayo D, et al : Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int 87 : 509-515, 2015.
5) Nayak SL, et al : Bile Cast Nephropathy in Patients with Acute Kidney Injury Due to Hepatorenal Syndrome : A Postmortem Kidney Biopsy Study. J Clin Transl Hepatol 5 : 92-100, 2017.
6) Sam R, et al : Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 37 : 1144-1151, 2001.
7) Jain K, et al : Bile cast nephropathy. Kidney Int 87 : 484, 2015.
8) 宮口祐樹, ほか : 維持透析療法を要した自己免疫性肝炎による胆汁円柱腎症に伴う肝腎症候群の一剖検例. 病理と臨床 37 : 911-918, 2019.
9) Fickert P, et al : Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology 58 : 2056-2069, 2013.
10) Bairaktari E, et al : Partially reversible renal tubular damage in patients with obstructive jaundice. Hepatology 33 : 1365-1369, 2001.
11) Sellinger M, et al : Sulfated bile acids inhibit Na+-H+ antiport in human kidney brush-border membrane vesicles. Am J Physiol 258 : F986-991, 1990.
12) Keklik M, et al : Treatment with plasma exchange may serve benefical effect in patients with severe hyperbilirubinemia : a single center experience. Transfus Apher Sci 48 : 323-326, 2013.
13) El Chediak A, et al : Bile cast nephropathy : when the kidneys turn yellow. Ren Replace Ther 6 : 15, 2020.
P.279 掲載の参考文献
2) Hata N, et al : Acute kidney injury and outcomes in acute decompensated heart failure : evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur J Heart Fail 12 : 32-37, 2010.
3) Shirakabe A, et al : Long-term prognostic impact after acute kidney injury in patients with acute heart failure. Int Heart J 53 : 313-319, 2012.
4) Shirakabe A, et al : Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J 77 : 687-696, 2013.
5) Shirakabe A, et al : Serum heart-type fatty acid-binding protein level can be used to detect acute kidney injury on admission and predict an adverse outcome in patients with acute heart failure. Circ J 79 : 119-128, 2015.
6) Shirakabe A, et al : The serum heart-type fatty acid-binding protein (HFABP) levels can be used to detect the presence of acute kidney injury on admission in patients admitted to the non-surgical intensive care unit. BMC Cardiovasc Disord 16 : 174, 2016.
7) Shirakabe A, et al : Clinical Usefulness of Urinary Liver Fatty Acid-Binding Protein Excretion for Predicting Acute Kidney Injury during the First 7 Days and the Short-Term Prognosis in Acute Heart Failure Patients with Non-Chronic Kidney Disease. Cardiorenal Med 7 : 301-315, 2017.
8) Shirakabe A, et al : Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 78 : 911-921, 2014.
11) Tsutsui H, et al : JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version. Circ J 83 : 2084-2184, 2019.
12) Shirakabe A, et al : Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure. ESC Heart Fail 5 : 322-331, 2018.
13) Shirakabe A, et al : Worsening renal failure in patients with acute heart failure : the importance of cardiac biomarkers. ESC Heart Fail 6 : 416-427, 2019.
14) Okazaki H, et al : The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol 68 : 384-391, 2016.
15) Okazaki H, et al : Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care. ESC Heart Fail 6 : 336-343, 2019.
16) Shirakabe A, et al : Hyperuricemia complicated with acute kidney injury is associated with adverse outcomes in patients with severely decompensated acute heart failure. Int J Cardiol Heart Vasc 23 : 100345, 2019.
P.284 掲載の参考文献
1) Hoen B, Duval X : Clinical practice. Infective endocarditis. N Engl J Med 368 : 1425-1433, 2013.
2) Nasr SH, et al : Bacterial infection-related glomerulonephritis in adults. Kidney Int 83 : 792-803, 2013.
3) Millaire A, et al : Incidence and prognosis of embolic events and metastatic infections in infective endocarditis. Eur Heart J 18 : 677-684, 1997.
4) Takata T, et al : Infective Endocarditis-Associated Glomerulonephritis : A Comprehensive Review of the Clinical Presentation, Histopathology, and Management. Yonago Acta Med 65 : 1-7, 2022.
5) Boils CL, et al : Update on endocarditis-associated glomerulonephritis. Kidney Int 87 : 1241-1249, 2015.
6) 藤井秀毅 : 慢性腎臓病における心不全. 腎と透析 90 : 76-81, 2021.
7) 成田一衛 : 抗菌薬による腎障害. 日本腎臓学会誌 58 : 1069-1072, 2016.
9) 日本循環器学会, ほか : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), 2018.
P.288 掲載の参考文献
2) Rangaswami J, et al : Cardiorenal Syndrome : Classification, Pathophysiology, Diagnosis, and Treatment Strategies : A Scientific Statement From the American Heart Association. Circulation 139 : e840-e878, 2019.
4) Ronco C, Di Lullo L : Cardiorenal syndrome in Western countries : epidemiology, diagnosis and management approaches. Kidney Dis (Basel) 2 : 151-163, 2017.
6) Mullens W, et al : Elevated intra-abdominal pressure in acute decompensated heart failure : a potential contributor to worsening renal function? J Am Coll Cardiol 51 : 300-306, 2008.
7) Damman K, et al : Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53 : 582-588, 2009.
9) Bayliss J, et al : Untreated heart failure : clinical and neuroendocrine effects of introducing diuretics. Br Heart J 57 : 17-22, 1987.
11) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
12) Damman K, et al : Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail 6 : 489-498, 2018.
13) McMurray JJV, et al : Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381 : 1995-2008, 2019.
P.291 掲載の参考文献
1) Guan WJ, et al : Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382 : 1708-1720, 2020.
2) Yang X, et al : Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China : a single-centered, retrospective, observational study. Lancet Respir Med 8 : 475-481, 2020.
3) Cheng Y, et al : Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97 : 829-838, 2020.
4) Hirsch JS, et al : Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98 : 209-218, 2020.
5) Bowe B, et al : Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clin J Am Soc Nephrol 16 : 14-25, 2020.
6) Joseph A, et al : Acute kidney injury in patients with SARS-CoV-2 infection. Ann Intensive Care 10 : 117, 2020.
7) Charytan DM, et al : Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness in New York City. Kidney Int Rep 6 : 916-927, 2021.
8) Chan L, et al : AKI in hospitalized patients with COVID-19. J Am Soc Nephrol 32 : 151-160, 2021.
9) Post A, et al : Kidney Infarction in Patients With COVID-19. Am J Kidney Dis 76 : 431-435, 2020.
10) Farkash EA, et al : Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. J Am Soc Nephrol 31 : 1683-1687, 2020.
11) Calomeni E, et al : Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. Kidney Int 98 : 233-234, 2020.
12) Santoriello D, et al : Postmortem Kidney Pathology Findings in Patients with COVID-19. J Am Soc Nephrol 31 : 2158-2167, 2020.
13) Sharma P, et al : COVID-19-Associated Kidney Injury : A Case Series of Kidney Biopsy Findings. J Am Soc Nephrol 31 : 1948-1958, 2020.
14) Akilesh S, et al : Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria. Am J Kidney Dis 77 : 82-93.e1, 2021.
15) Kissling S, et al : Collapsing glomerulopathy in a COVID-19 patient. Kidney Int 98 : 228-231, 2020.
16) Uppal NN, et al : De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 5 : 2079-2083, 2020.
17) Prendecki M, et al : Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int 98 : 780-781, 2020.
18) Huang Y, et al : Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy : a case report. BMC Nephrol 21 : 504, 2020.
19) Williamson EJ, et al : Factors associated with COVID-19-related death using OpenSAFELY. Nature 584 : 430-436, 2020.
20) 日本透析医会・日本透析医学会・日本腎臓学会新型コロナウイルス感染対策合同委員会透析患者における累積の新型コロナウイルス感染症の登録数. (2022年6月17日付)
21) 厚生労働省 : 新型コロナウイルス感染症について国内の発生状況など. [https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html#h2_1]
22) Lopes RD, et al : Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19 : A Randomized Clinical Trial. JAMA 325 : 254-264, 2021.
23) Negrea L, Rovin BH : Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int 99 : 1487, 2021.
24) Lebedev L, et al : Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 78 : 142-145, 2021.
25) Aydin MF, et al : Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int 100 : 464-465, 2021.
26) Ville S, et al : Atypical HUS relapse triggered by COVID-19. Kidney Int 99 : 267-268, 2021.
27) Anderegg MA, et al : De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int 100 : 474-476, 2021.
28) Tan HZ, et al : Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 100 : 469-471, 2021.
29) Wu HHN, et al : New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination : A Systematic Review. Vaccines (Basel) 9 : 1252, 2021.
30) Matsuzaki K, et al : Gross hematuria after SARS-CoV-2 vaccination : questionnaire survey in Japan. Clin Exp Nephrol 26 : 316-322, 2022.
P.297 掲載の参考文献
1) Gardner SD, et al : New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1 : 1253-1257, 1971.
2) Purighalla R, et al : BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 26 : 671-673, 1995.
3) Knowles WA, et al : Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71 : 115-123, 2003.
4) Levican J, et al : Role of BK human polyomavirus in cancer. Infect Agent Cancer 13 : 12, 2018.
5) Wunderink HF, et al : Source and Relevance of the BK Polyomavirus Genotype for Infection After Kidney Transplantation. Open Forum Infect Dis 6 : ofz078, 2019.
6) Masutani K, et al : Putative episodes of T-cell-mediated rejection in patients with sustained BK viruria but no viremia. Transplantation 94 : 43-49, 2012.
7) Pham PT, et al : BK virus infection following kidney transplantation : an overview of risk factors, screening strategies, and therapeutic interventions. Curr Opin Organ Transplant 19 : 401-412, 2014.
8) Hirsch HH, Randhawa PS ; AST Infectious Diseases Community of Practice : BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33 : e13528, 2019.
9) Haas M, et al : Banff 2013 meeting report : inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 14 : 272-283, 2014.
10) Nickeleit V, et al : The Banff Working Group Classification of Definitive Polyomavirus Nephropathy : Morphologic Definitions and Clinical Correlations. J Am Soc Nephrol 29 : 680-693, 2018.
11) Nickeleit V, et al : The 2018 Banff Working Group classification of definitive polyomavirus nephropathy : A multicenter validation study in the modern era. Am J Transplant 21 : 669-680, 2021.
12) Hariharan S : BK virus nephritis after renal transplantation. Kidney Int 69 : 655-662, 2006.
P.302 掲載の参考文献
1) 柳澤如樹 : わが国のHIV感染者における慢性腎臓病の有病率と予後に関する研究. 日本エイズ学会誌 21 : 70-78, 2019.
4) Zhong J, et al : Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int 68 : 1048-1060, 2005.
5) Lescure FX, et al : HIV-associated kidney glomerular diseases : changes with time and HAART. Nephrol Dial Transplant 27 : 2349-2355, 2012.
6) Wyatt CM, et al : HIV-associated nephropathy : clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol 28 : 513-522, 2008.
8) Winston JA, et al : Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 344 : 1979-1984, 2001.
9) 日本エイズ学会HIV感染症治療委員会 : 抗HIV療法の目標. HIV感染症「治療の手引き」, 第25版, p10, 2021.
12) Wyatt CM : Kidney Disease and HIV Infection. Top Antivir Med 25 : 13-16, 2017.
13) Berns JS, Kasbekar N : Highly active antiretroviral therapy and the kidney : an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 1 : 117-129, 2006.
14) Zimmermann AE, et al : Tenofovir-associated acute and chronic kidney disease : a case of multiple drug interactions. Clin Infect Dis 42 : 283-290, 2006.
15) Krummel T, et al : Tenofovir-induced acute renal failure in an HIV patient with normal renal function. Nephrol Dial Transplant 20 : 473-474, 2005.
P.307 掲載の参考文献
1) Satoskar AA, et al : Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol 16 : 32-50, 2020.
3) Nasr SH, et al : IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol 34 : 1235-1241, 2003.
4) Satoskar AA, et al : Staphylococcus Infection-Associated GN-Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort. Clin J Am Soc Nephrol 12 : 39-49, 2017.
5) Usui J, et al : Methicillin-resistant Staphylococcus-aureus-associated glomerulonephritis on the decline : decreased incidence since the 1990s. Clin Exp Nephrol 15 : 184-186, 2011.
6) Bu R, et al : Clinicopathologic features of IgA-dominant infection-associated glomerulonephritis : a pooled analysis of 78 cases. Am J Nephrol 41 : 98-106, 2015.
8) Kobayashi M, Koyama A : Methicillin-resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis-a novel hazard emerging on the horizon. Nephrol Dial Transplant 13 : 2999-3001, 1998.
9) 清水芳男 : MRSA関連腎炎. 専門医のための腎臓病学 [第2版] (下条文武監, 内山聖, ほか編), p291-295, 医学書院, 2009.
10) Koyama A, et al : Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int 66 : 121-132, 2004.
11) 下畑誉, 小林正貴 : MRSA感染後糸球体腎炎. 腎と透析 76 : 329-334, 2014.
P.310 掲載の参考文献
1) Flomenberg P, Kojaoghlanian T : Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection. In : UpToDate, Post TW (Ed), UpToDate, Waltham, MA. [https://www.uptodate.com/contents/pathogenesis-epidemiology-and-clinical-manifestations-ofadenovirus-infection]
2) Lusco MA, et al : AJKD Atlas of Renal Pathology : Adenovirus Infection. Am J Kidney Dis 71 : e1-e2, 2018.
3) Al-Heeti OM, et al : Adenovirus Infection and Transplantation. Transplantation 106 : 920-927, 2022.
4) Lynch JP 3rd, Kajon AE : Adenovirus : Epidemiology, Global Spread of Novel Types, and Approach to Treatment. Semin Respir Crit Care Med 42 : 800-821, 2021.
5) Florescu MC, et al : What do we know about adenovirus in renal transplantation? Nephrol Dial Transplant 28 : 2003-2010, 2013.
6) Parasuraman R, et al : Severe necrotizing adenovirus tubulointerstitial nephritis in a kidney transplant recipient. Case Rep Transplant 2013 : 969186, 2013.
8) Birlutiu V, Birlutiu RM : Haemolytic-uremic syndrome due to infection with adenovirus : A case report and literature review. Medicine (Baltimore) 97 : e9895, 2018.
10) Saliba M, et al : Adenovirus infection as a cause of fever of unknown origin and allograft dysfunction in a kidney transplant recipient. Exp Clin Transplant 17 : 411-413, 2019.
11) Munoz F, Flomenberg P : Diagnosis, treatment, and prevention of adenovirus infection. In : UpToDate, Post TW (Ed), UpToDate, Waltham, MA. [https://www.uptodate.com/contents/diagnosis-treatment-and-prevention-of-adenovirus-infection]
12) Veer M, et al : Adenoviral nephritis in a renal transplant recipient : Case report and literature review. Transpl Infect Dis 19 : e12716, 2017.
13) 川満紀子, ほか : 尿沈渣中の細胞形態と迅速診断キットの併用からアデノウイルス性出血性膀胱炎の診断に至った症例. 医学検査 70 : 150-154, 2021.
P.315 掲載の参考文献
1) 林谷秀樹 : Yersinia感染症. 日本食品微生物学会雑誌 33 : 175-181, 2016.
2) 武田修明 : エルシニア感染症. 小児科診療 64 : 1030-1035, 2001.
3) Koo JW, et al : Acute renal failure associated with Yersinia pseudotuberculosis infection in children. Pediatr Nephrol 10 : 582-586, 1996.
4) 石川智朗 : エルシニア感染症腎臓専門医の視点より. 腎と透析 86 (増刊号 : 全身性疾患と腎update) : 380-383, 2019.
5) Abe J, et al : Evidence for superantigen production by Yersinia pseudotuberculosis. J Immunol 151 : 4183-4188, 1993.
6) Uchiyama T, et al : Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute and systemic symptoms. J Immunol 151 : 4407-4413, 1993.
7) Yoshino K, et al : Geographical heterogeneity between Far East and Europe in prevalence of ypm gene encoding the novel superantigen among Yersinia pseudotuberculosis strains. J Clin Microbiol 33 : 3356-3358, 1995.
9) 阿部淳 : エルシニア感染症とスーパー抗原. 医学のあゆみ 193 : 887-890, 2000.
10) 石川智朗, ほか : エルシニア間質性腎炎の診断における抗YPM抗体の有用性. 日児腎誌 (Suppl) 25 : 258, 2012.
11) 深山雄大, ほか : Yersinia pseudotuberculosis感染による急性尿細管間質性腎炎リスクファクターの検討. 日本小児腎臓病学会雑誌 26 : 187-193, 2014.
12) 酒井菜那, ほか : LAMP法により早期に検出した, 急性腎不全を合併したYersinia pseudotuberculosis感染症の1例. 日本小児腎臓病学会雑誌 23 : 102-106, 2010.
P.319 掲載の参考文献
1) Saikku P, et al : Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2 : 983-986, 1988.
2) JB Mahony JB, Coombes BK : Chlamydia pneumoniae and atherosclerosis : does the evidence support a causal or contributory role? FEMS Microbiol Lett 197 : 1-9, 2001.
3) Bellomo G, et al : Inflammation, infection and cardiovascular events in chronic hemodialysis patients : a prospective study. J Nephrol 16 : 245-251, 2003.
5) Worm HC, et al : High prevalence of Chlamydia pneumoniae infection in cyclosporin A-induced post-transplant gingival overgrowth tissue and evidence for the possibility of persistent infection despite short-term treatment with azithromycin. Nephrol Dial Transplant 19 : 1890-1894, 2004.
6) 石宇, 徳永藏 : 多重感染と動脈硬化. 脈管学 43 : 667-671, 2003.
7) O'Connor CM, et al : Azithromycin for the secondary prevention of coronary heart disease events : the WIZARD study : a randomized controlled trial. JAMA 290 : 1459-1466, 2003.
8) 平山貴博, ほか : 腎後性腎不全を契機に発見されたクラミジア性骨盤内炎症の1例. 泌尿器科紀要 54 : 301-304, 2008.
9) 福家吉伸, ほか : Chlamydia trachomatis (C.trachomatis) の腹腔内感染を契機に発症したと考えられるIgA腎症の2症例. 日本腎臓学会誌会議録 48 : 591, 2006.
10) 四類感染症/五類感染症. オウム病, p26 ; 性器クラミジア感染症, p84 ; クラミジア肺炎, p88, 感染症法に基づく医師の届出基準 (日本医師会編), 中央法規出版, 2006.
11) Ward ME : Chlamydial classification, development and structure. Br Med Bull 39 : 109-115, 1983.
12) 岸本寿男, 小川基彦 : 内科領域におけるクラミジア感染症. 医学のあゆみ 203 : 407-410, 2002.
13) 性感染症診断・治療ガイドライン 2020 (日本性感染症学会編), 診断と治療社, 2020.
14) Herrera-Insua I, et al : Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes. Eur J Clin Microbiol Infect Dis 16 : 13-16, 1997.
15) Anderson DL : Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc) 44 : 489-501, 2008.
16) 腎機能低下時の薬剤投与量. CKD診療ガイド 2012 (日本腎臓学会編), p120-125, 東京医学社, 2012.
P.324 掲載の参考文献
1) Satoskar AA, et al : Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol 16 : 32-50, 2020.
2) Black JA, et al : Nephrotic syndrome associated with bacteraemia after shunt operations for hydrocephalus. Lancet 2 : 921-924, 1965.
3) Arze RS, et al : Shunt nephritis : report of two cases and review of the literature. Clin Nephrol 19 : 48-53, 1983.
5) Okada M, et al : Central venous catheter infection-related glomerulonephritis under long-term parenteral nutrition : a report of two cases. BMC Res Notes 9 : 196, 2016.
6) Babigumira M, et al : Delayed Manifestation of Shunt Nephritis : A Case Report and Review of the Literature. Case Rep Nephrol 2017 : 1867349, 2017.
7) Narchi H, et al : Shunt nephritis. J Pediatr Surg 23 : 839-841, 1988.
8) Al-Schameri AR, et al : Ventriculoatrial Shunts in Adults, Incidence of Infection, and Significant Risk Factors : A Single-Center Experience. World Neurosurg 94 : 345-351, 2016.
10) Schena FP, et al : Circulating immune complexes in infected ventriculoatrial and ventriculoperitoneal shunts. J Clin Immunol 3 : 173-177, 1983.
11) Kiryluk K, et al : A young man with Propionibacterium acnes-induced shunt nephritis. Kidney Int 73 : 1434-1440, 2008.
12) Wald SL, McLaurin RL : Shunt-associated glomerulonephritis. Neurosurgery 3 : 146-150, 1978.
13) ter Borg EJ, et al : Transient arthritis with positive tests for rheumatoid factor as presenting sign of shunt nephritis. Ann Rheum Dis 50 : 182-183, 1991.
14) Nasr SH, et al : Bacterial infection-related glomerulonephritis in adults. Kidney Int 83 : 792-803, 2013.
15) Ajlan B, et al : Timing of ventriculoatrial shunt removal on renal function recovery of patients with shunt nephritis : Case report and systematic review. Clin Neurol Neurosurg 218 : 107279, 2022.
16) Ono H, et al : Shunt Nephritis and Pyogenic Spondylitis With a Positive PR3-ANCA Associated With Chronically Infected Ventriculoatrial Shunt. Kidney Int Rep 2 : 774-778, 2017.
P.328 掲載の参考文献
1) Yanagihara Y, et al : Leptospira is an environmental bacterium that grows in waterlogged soil. Microbiol Spectr 10 : e0215721, 2022.
3) 増澤俊幸 : 厚生労働科学研究費補助金新興・再興感染症研究事業回帰熱, レプトスピラ等の希少輸入細菌感染症の実態調査及び迅速診断法の確立に関する研究 平成12年度~14年度総合研究報告書, 2003.
4) Saito M, et al : The usefulness of semi-solid medium in the isolation of highly virulent Leptospira strains from wild rats in an urban area of Fukuoka, Japan. Microbiol Immunol 59 : 322-330, 2015.
5) Yang CW : Leptospirosis renal disease : emerging culprit of chronic kidney disease unknown etiology. Nephron 138 : 129-136, 2018.
6) Ozuru R, et al : Adipose tissue is the first colonization site of Leptospira interrogans in subcutaneously infected hamsters. PLoS One 12 : e0172973, 2017.
7) Miyahara S, et al : Destruction of the hepatocyte junction by intercellular invasion of Leptospira causes jaundice in a hamster model of Weil's disease. Int J Exp Pathol 95 : 271-281, 2014.
9) Yang CW, et al : Toll-like receptor 2 mediates early inflammation by leptospiral outer membrane proteins in proximal tubule cells. Kidney Int 69 : 815-822, 2006.
10) 大田南欧美, ほか : 発熱, 肝障害, 血小板減少を伴い急性腎障害をきたしたレプトスピラ症の1例. 日本内科学会雑誌 107 : 2147-2153, 2018.
11) Herath NJ, et al : Long term outcome of acute kidney injury due to leptospirosis? A longitudinal study in Sri Lanka. BMC Res Notes 7 : 398, 2014.
12) Maruoka T, et al : Correlation between renal distribution of leptospires during the acute phase and chronic renal dysfunction in a hamster model of infection with Leptospira interrogans. PLoS Negl Trop Dis 15 : e0009410, 2021.
13) 齋藤光正, ほか : レプトスピラ感染症の検査法の現状. 臨床微生物迅速診断研究会誌 27 : 65-72, 2017.
14) 小林譲 : レプトスピラ病の臨床と診断, 治療. 化学療法の領域 17 : 2137-2145, 2001.
P.332 掲載の参考文献
1) He J, et al : Insights into the pathogenesis of Mycoplasma pneumoniae (Review). Mol Med Rep 14 : 4030-4036, 2016.
6) Kaneko K, et al : Mycoplasma pneumoniae-associated Henoch-Schonlein purpura nephritis. Pediatr Nephrol 13 : 1000-1001, 1999.
11) Chen X, et al : Acute postinfectious glomerulonephritis with a large number of crescents caused by Mycoplasma pneumoniae. Indian J Pathol Microbiol 58 : 374-376, 2015.
12) Lee H, et al : Cutaneous vasculitis and renal involvement in Mycoplasma pneumoniae infection. Korean J Intern Med 30 : 402-405, 2015.
13) Hirano D, et al : Glyceraldehyde-3-phosphate dehydrogenase of Mycoplasma pneumoniae induces infection-related glomerulonephritis. Clin Nephrol 92 : 263-272, 2019.
14) Aizawa T, et al : Membranous nephropathy associated with Mycoplasma pneumoniae infection. Pediatr Int 63 : 853-855, 2021.
P.337 掲載の参考文献
1) 山藤栄一郎 : リケッチア感染症-日本紅斑熱とツツガムシ病をどのように疑い, 診断・治療するか. Hospitalist 5 : 519-528, 2017.
3) Yen TH, et al : Scrub typhus : a frequently overlooked cause of acute renal failure. Ren Fail 25 : 397-410, 2003.
4) 馬原文彦 : 発疹と高熱を主徴としWeil-Felix 反応 (OX2) 陽性を示した3症例について. 阿南医報 68 : 4-7, 1984.
5) Sando E, et al : Rickettsia japonica Infection after Land Leech Bite, Japan. Emerg Infect Dis 25 : 1243-1245, 2019.
6) Akter A, et al : Extremely Low Genomic Diversity of Rickettsia japonica Distributed in Japan. Genome Biol Evol 9 : 124-133, 2017.
8) Sando E, et al : Distinguishing Japanese Spotted Fever and Scrub Typhus, Central Japan, 2004-2015. Emerg Infect Dis 24 : 1633-1641, 2018.
9) 国立感染症研究所 : つつが虫病・日本紅斑熱 2007~2016年. IASR 38 : 109-112, 2017.
10) Taylor AJ, et al : A Systematic Review of Mortality from Untreated Scrub Typhus (Orientia tsutsugamushi). PLoS Negl Trop Dis 9 : e0003971, 2015.
11) 国立感染症研究所 : 日本紅斑熱 1999~2019年. IASR 41 : 133-135, 2020.
12) Sando E, et al : Serological Cross-Reactivity among Orientia tsutsugamushi Serotypes but Not with Rickettsia japonica in Japan. Trop Med Infect Dis 3 : 74, 2018.
13) Sando E, et al : Case Report : Concurrent Sympatric Scrub Typhus and Japanese Spotted Fever in Japan. Am J Trop Med Hyg 99 : 1386-1389, 2018.
14) 平良雅克, ほか : 関東地方で初めて感染が確認された重症熱性血小板減少症候群の1例. IASR 42 : 150-152, 2021.
15) Kawaguchi T, et al : Impact of C-Reactive Protein Levels on Differentiating of Severe Fever With Thrombocytopenia Syndrome From Japanese Spotted Fever. Open Forum Infect Dis 7 : ofaa473, 2020.
16) Park SW, et al : Severe fever with thrombocytopenia syndrome : comparison with scrub typhus and clinical diagnostic prediction. BMC Infect Dis 19 : 174, 2019.
17) Biggs HM, et al : Diagnosis and Management of Tickborne Rickettsial Diseases : Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis-United States. MMWR Recomm Rep 65 : 1-44, 2016.
18) Cunha BA, et al : Similarities and differences between doxycycline and minocycline : clinical and antimicrobial stewardship considerations. Eur J Clin Microbiol Infect Dis 37 : 15-20, 2018.
19) El Sayed I, et al : Antibiotics for treating scrub typhus. Cochrane Database Syst Rev 9 : CD002150, 2018.
P.343 掲載の参考文献
1) Sato T, et al : Cost-effectiveness analysis of a universal rotavirus immunization program in Japan. Jpn J Infect Dis 64 : 277-283, 2011.
2) Morita T, Fujieda M : Acidosis with hyperuricemia and renal tubular damage in viral gastroenteritis. Pediatr Nephrol 26 : 2259-2260 ; author reply 2261, 2011.
3) Kovacs A, et al : Rotavirus gastroenteritis. Clinical and laboratory features and use of the Rotazyme test. Am J Dis Child 141 : 161-166, 1987.
5) Fujita T, et al : Acute renal failure due to obstructive uric acid stones associated with acute gastroenteritis. Pediatr Nephrol 24 : 2467-2469, 2009.
7) Kira S, et al : Postrenal failure due to urinary stones associated with acute viral gastroenteritis : three case reports. Case Rep Urol 2016 : 1375923, 2016.
8) Tsukida K, et al : Rotavirus gastroenteritis-associated urinary tract calculus in an infant. Turk J Pediatr 60 : 769-770, 2018.
9) Ashida A, et al : Clinical characteristics of obstructive uropathy associated with rotavirus gastroenteritis in Japan. Clin Nephrol 77 : 49-54, 2012.
10) Shirasu A, et al : Clinical characteristics of rotavirus gastroenteritis with urinary crystals. Pediatr Int 57 : 917-921, 2015.
12) Dick WH, et al : Laxative abuse as a cause for ammonium urate renal calculi. J Urol 143 : 244-247, 1990.
13) Hesse A, et al : Ammonium urate stones. In : Urinary Stones-Diagnosis, Treatment, and Prevention of Recurrence, 2nd ed, p160-172, Karger, Basel, 2002.
14) Soble JJ, et al : Ammonium acid urate calculi : a reevaluation of risk factors. J Urol 161 : 869-873, 1999.
15) Matsuo H, et al : Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2. Sci Rep 6 : 31003, 2016.
P.347 掲載の参考文献
1) Ljungman P, et al : Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis 64 : 87-91, 2017.
2) Ho M : Epidemiology of cytomegalovirus infections. Rev Infect Dis 12 (Suppl 7) : S701-710, 1990.
3) 千場勉, ほか : 妊婦のサイトメガロウイルス抗体保有率の低下. 日本臨牀 56 : 193-196, 1998.
5) Wong KM, et al : Cytomegalovirus-induced tubulointerstitial nephritis in a renal allograft treated by foscarnet therapy. Am J Nephrol 20 : 222-224, 2000.
6) Chou S : Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis 12 (Suppl 7) : S727-736, 1990.
7) Eguchi H, et al : Diagnostic test accuracy of antigenaemia assay for PCR-proven cytomegalovirus infection-systematic review and meta-analysis. Clin Microbiol Infect 23 : 907-915, 2017.
8) Kotton CN, et al : The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 102 : 900-931, 2018.
9) 西慎一 : ウイルス感染に伴う間質性腎障害. 日本腎臓学会誌 53 : 620-624, 2011.
10) 谷澤雅彦 : 抗ウイルス薬による尿細管機能障害. 日本内科学会雑誌 107 : 878-887, 2018.
11) 相川厚 : 腎移植後サイトメガロウイルス感染症の診療ガイドライン. 移植 49 : 402-409, 2014.
12) Hantz S, et al : Drug-resistant cytomegalovirus in transplant recipients : a French cohort study. J Antimicrob Chemother 65 : 2628-2640, 2010.
13) Leowattana W : Antiviral drugs and acute kidney injury (AKI). Infect Disord Drug Targets 19 : 375-382, 2019.
P.352 掲載の参考文献
2) 島田美智子, 山辺英彰 : ウイルス性肝炎. 日本内科学会雑誌 100 : 1308-1312, 2011.
3) Johnson RJ, Shimada M : Contemporary Management of Hepatitis C in Patients with CKD. Clin J Am Soc Nephrol 12 : 1563-1565, 2017.
4) Fornasieri A, et al : High binding of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular fibronectin : a mechanism for induction of in situ immune complex glomerulonephritis? Am J Kidney Dis 27 : 476-483, 1996.
5) Yamabe H, et al : Hepatitis C virus-associated glomerulonephritis without hepatitis C virus in the blood. Am J Kidney Dis 46 : e65-69, 2005.
6) 吉川賢二, ほか : C型慢性肝炎に合併した膜性腎症の1例. 日本小児腎臓病学会雑誌 9 : 21-25, 1996.
7) Weng Q, et al : Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir : a case report and review of literature. Oncotarget 8 : 22299-22303, 2017.
8) Kidney Disease : Improving Global Outcomes (KDIGO) Hepatitis C Work Group : KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 8 : 91-165, 2018.
11) Beck LH, Salant DJ : Membranous nephropathy : from models to man. J Clin Invest 124 : 2307-2314, 2014.
12) Mazzaro C, et al : Hepatitis B Virus-Related Cryoglobulinemic Vasculitis : Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos (t) ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). Viruses 13 : 1032, 2021.
13) Wang R, et al : Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection. Sci Rep 11 : 18407, 2021.
14) Connor FL, et al : HBV associated nephrotic syndrome : resolution with oral lamivudine. Arch Dis Child 88 : 446-449, 2003.
15) Igarashi T, et al : Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy. J Nippon Med Sch 80 : 387-395, 2013.
P.356 掲載の参考文献
2) Pontin AR, et al : Emphysematous pyelonephritis in diabetic patients. Br J Urol 75 : 71-74, 1995.
3) Kelly HA : Pneumaturia MCWG. JAMA 31 : 375-381, 1898.
4) 黒田治朗, ほか : 気腫性腎盂腎炎の1例. 泌尿器科紀要 20 : 141-147, 1974.
5) Pode D, et al : Emphysematous renal and perirenal infection in nondiabetic patient. Urology 26 : 313-315, 1985.
6) Kitano H, et al : Case Report : Emphysematous Pyelonephritis With a Congenital Giant Ureterocele. Front Pediatr 9 : 775468, 2021.
7) Cao BL, et al : Emphysematous cystitis with bilateral pyelonephritis in a pediatric patient with COVID-19. BMJ Case Rep 15 : e245779, 2022.
8) Desai R, Batura D : A systematic review and meta-analysis of risk factors and treatment choices in emphysematous pyelonephritis. Int Urol Nephrol 54 : 717-736, 2022.
9) Falagas ME, et al : Risk factors for mortality in patients with emphysematous pyelonephritis : a meta-analysis. J Urol 178 : 880-885 ; quiz 1129, 2007.
10) Kone K, et al : Mortality in emphysematous pyelonephritis : Can we reduce it further by using a protocol-based treatment? The results of a prospective study. Urol Ann 14 : 73-80, 2022.
11) Aswathaman K, et al : Emphysematous pyelonephritis : outcome of conservative management. Urology 71 : 1007-1009, 2008.
12) 野村博之, ほか : 糖尿病に合併した気腫性腎盂腎炎の2例と本邦報告例119例の臨床的検討. 西日本泌尿器科 66 : 23-29, 2004.
14) Huang JJ, Tseng CC : Emphysematous pyelonephritis : clinicoradiological classification, management, prognosis, andpathogenesis. Arch Intern Med 160 : 797-805, 2000.
15) Sengupta S, Basu S : Outcome of conservative and minimally invasive management in emphysematous pyelonephritis. Urol Ann 13 : 277-281, 2021.
16) Lin WC, et al : Reappraisal of the management and outcome of emphysematous pyelonephritis. Kaohsiung J Med Sci 25 : 16-24, 2009.
P.362 掲載の参考文献
1) 荒川創一, ほか : 尿路性器感染症に関する臨床試験実施のためのガイドライン-第2版-. 日本化学療法学会雑誌 64 : 479-493, 2016.
2) 一般社団法人日本感染症学会, 公益社団法人日本化学療法学会JAID/JSC感染症治療ガイド・ガイドライン作成委員会尿路感染症・男性性器感染症ワーキンググループ ; 山本新吾, ほか : JAID/JSC感染症治療ガイドライン 2015-尿路感染症・男性性器感染症-. 感染症学雑誌 90 : 1-30, 2016.
3) 松本哲朗, ほか : 尿路感染症主要原因菌の各種抗菌薬に対する感受性. 日本化学療法学会雑誌 58 : 466-482, 2010.
4) 日本化学療法学会UTI薬効評価基準見直しのための委員会 ; 松本哲朗 : 尿路感染症. 新泌尿器科学 改訂4版 (内藤誠二編), p143-155, 南山堂, 2001.
5) 松本哲朗, ほか : 尿路性器感染症に関する臨床試験実施のためのガイドライン-第1版-. 日本化学療法学会雑誌 57 : 511-525, 2009.
6) Jodal U : The natural history of bacteriuria in childhood. Infect Dis Clin North Am 1 : 713-729, 1987.
P.368 掲載の参考文献
1) Michaelis L, Gutmann C : Ueber einschlusse in blasentumoren. Z Klin Med 47 : 208-215, 1902.
2) Deridder PA, et al : Renal malacoplakia. J Urol 117 : 428-432, 1977.
3) Dobyan DC, et al : Renal malacoplakia reappraised. Am J Kidney Dis 22 : 243-252, 1993.
4) Hurwitz G, et al : Bilateral renal parenchymal malacoplakia : a case report. J Urol 147 : 115-117, 1992.
5) Kobayashi A, et al : Malakoplakia of the kidney. Am J Kidney Dis 51 : 326-330, 2008.
6) Tam VK, et al : Renal parenchymal malacoplakia : a rare cause of ARF with a review of recent literature. Am J Kidney Dis 41 : E13-17, 2003.
7) Kinsella PM, et al : Successful use of azithromycin for Escherichia coli-associated renal allograft malakoplakia : a report of two cases. Eur J Clin Microbiol Infect Dis 40 : 2627-2631, 2021.
8) Patel MR, et al : Renal graft malakoplakia masquerading post-transplant lymphoproliferative disorder. BMJ Case Rep 14 : e244228, 2021.
9) Mookerji N, et al : Case-Malakoplakia in a 58-year-old male following living donor renal transplantation. Can Urol Assoc J 13 : E19-21, 2019.
10) Graves AL, et al : Successful treatment of renal allograft and bladder malakoplakia with minimization of immunosuppression and prolonged antibiotic therapy. Nephrology (Carlton) 19 (Suppl 1) : 18-21, 2014.
11) Honsova E, et al : Cured malakoplakia of the renal allograft followed by long-term good function : A case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 156 : 180-182, 2012.
12) Augusto JF, et al : Renal transplant malakoplakia : case report and review of the literature. NDT Plus 1 : 340-343, 2008.
13) Puerto IM, et al : Renal malakoplakia as a pseudotumoral lesion in a renal transplant patient : a case report. Int J Urol 14 : 655-657, 2007.
14) Pirojsakul K, et al : Mass lesions in the transplanted kidney : Answers. Pediatr Nephrol 30 : 1109-1111, 2015.
15) Pusl T, et al : Malacoplakia in a renal transplant recipient. Eur J Intern Med 17 : 133-135, 2006.
16) Merritt AJ, et al : Malakoplakia diagnosed by fine needle aspiration (FNA) and liquid-based cytology (LBC) presenting as a pararenal mass in a transplant kidney. Cytopathology 25 : 276-277, 2014.
P.376 掲載の参考文献
1) 各論 第1部 : 人体寄生原虫学. 図説人体寄生虫学 [改訂10版] (吉田幸雄原著, 日本寄生虫学会「図説人体寄生虫学」編集委員会編), p24-86, 南山堂, 2021.
2) Brandt H, et al : Pathology of human amebiasis. Hum Pathol 1 : 351-385, 1970.
3) Andrew WK, et al : Renal amoebic abscess detected on grey-scale ultrasonography. A case report. S Afr Med J 59 : 571-574, 1981.
5) Sharma A, et al : Amoebic renal cyst : a case report. Braz J Infect Dis 9 : 266-268, 2005.
6) 寄生虫症薬物治療の手引き-2020- [改訂第10.2版] (日本医療研究開発機構新興・再興感染症に対する革新的医薬品等開発推進研究事業「わが国における熱帯病・寄生虫症の最適な診断治療予防体制の構築」 (略称 : 熱帯病治療薬研究班) 編), 2020.
7) Gilles HM, et al : Possible aetiological role of Plasmodium malariae in "nephrotic syndrome" in Nigerian children. Lancet 1 : 806-807, 1960.
8) Boonpucknavig V, et al : Pathology of renal diseases in the tropics. Semin Nephrol 23 : 88-106, 2003.
9) Sitprija V, Boonpucknavig V : Renal involvement in parasitic diseases. In : Renal Pathology with Clinical and Functional Correlations, 2nd ed (ed by Tisher CC, Brenner BM), p626-657, J. B. Lippincott, Philadelphia, 1994.
10) Soni PN, et al : Severe and complicated malaria in KwaZulu-Natal. S Afr Med J 86 : 653-656, 1996.
11) Nagle RB, et al : Glomerular accumulation of monocytes and macrophages in experimental glomerulonephritis associated with Trypanosoma rhodesiense infection. Lab Invest 46 : 365-376, 1982.
12) Barret-Connor E, et al : Disseminated intravascular coagulation in trypanosomiasis. Arch Intern Med 131 : 574-577, 1973.
13) Kierszenbaum F : Autoimmunity in Chagas' disease. J Parasitol 72 : 201-211, 1986.
14) Tewarson SL, et al : Amyloidosis kidney with filariasis presenting as nephrotic syndrome : Incidental finding or unusual association? Trop Med Health 36 : 185-187, 2008.
15) 小泉孔二, ほか : Povidone Iodine 腎盂内注入療法が著効を示した特発性乳び尿の1例. 泌尿器科紀要 54 : 615-617, 2008.
16) Lan WH, et al : A comparison of retroperitoneoscopic and open surgical renal pedicle lymphatic disconnection for the treatment of serious filarial chyluria. Chin Med J (Engl) 120 : 932-934, 2007.
17) Barsoum RS : Schistosomiasis and the kidney. Semin Nephrol 23 : 34-41, 2003.
18) 藤本順一郎, ほか : 肝硬変と膜性増殖性糸球体腎炎様病変を合併した日本住血吸虫症の1剖検例. 奈良医学雑誌 41 : 319-324, 1990.
19) Chang AH, et al : Tuberculosis and Parasitic Infections of the Genitourinary Tract. In : Campbell-Walsh-Wein Urology, 12th ed (ed by Partin AW, et al), p1307-1332, Elsevier, Philadelphia, 2021.
20) Baijal SS, et al : Percutaneous management of renal hydatidosis : a minimally invasive therapeutic option. J Urol 153 : 1199-1201, 1995.
22) Rabii R, et al : Laparoscopic treatment for renal hydatid cyst. J Endourol 20 : 199-201, 2006.
23) Khan M, et al : Retroperitoneal laparoscopy for the management of renal hydatid cyst. Int J Surg 8 : 266-268, 2010.
24) Divarci E, et al : Retroperitoneoscopic laparoscopic treatment of renal hydatid cyst in a child. J Pediatr Surg 45 : 262-264, 2010.
25) Unsal A, et al : An unusual cause of renal colic : hydatiduria. Int J Urol 8 : 319-321, 2001.
26) Sountoulides P, et al : Nephrectomy for benign disease? A case of isolated renal echinococcosis. Int J Urol 13 : 174-176, 2006.
P.380 掲載の参考文献
1) Corbett EL, et al : The growing burden of tuberculosis : global trends and interactions with the HIV epidemic. Arch Intern Med 163 : 1009-1021, 2003.
2) World Health Organization : Global Tuberculosis report 2021. [https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021]
3) Cohen A, et al : The global prevalence of latent tuberculosis : a systematic review and metaanalysis. Eur Respir J 54 : 1900655, 2019.
4) Kizza FN, et al : Prevalence of latent tuberculosis infection and associated risk factors in an urban African setting. BMC Infect Dis 15 : 165, 2015.
5) Hagiya H, et al : Trends in incidence and mortality of tuberculosis in Japan : A population-based study, 1997-2016. Epidemiol Infect 147 : e38, 2019.
6) 結核予防会結核研究所疫学情報センター : 年報 2020. [https://jata-ekigaku.jp/wpcontent/uploads/2022/06/2020_shiryohen.pdf]
8) Hagiya H, et al : Mortar kidney. Intern Med 60 : 1481, 2021.
9) Conte G, et al : Acute renal failure of unknown origin. Don't forget renal tuberculosis. Nephrol Dial Transplant 12 : 1260-1261, 1997.
10) Golden MP, Vikram HR : Extrapulmonary tuberculosis : an overview. Am Fam Physician 72 : 1761-1768, 2005.
11) Kafwabulula M, et al : Evaluation of PCR-based methods for the diagnosis of tuberculosis by identification of mycobacterial DNA in urine samples. Int J Tuberc Lung Dis 6 : 732-737, 2002.
13) Shu CC, et al : Hepatotoxicity due to first-line anti-tuberculosis drugs : a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 17 : 934-939, 2013.
14) 日本結核・非結核性抗酸菌症学会治療委員会 : 本邦での多剤耐性結核治療に対する考え方, 2020. [https://www.kekkaku.gr.jp/pub/pdf/MultidrugResistantTuberculosisTreatment.pdf
15) Mochalova TP, Starikov IY : Reconstructive surgery for treatment of urogenital tuberculosis : 30 years of observation. World J Surg 21 : 511-515, 1997.
P.384 掲載の参考文献
1) Schaeffer AJ : Infection of the urinary tract. In : Campbell-Walsh Urology, 9th ed (ed by Wein AJ, et al), Vol 1, p273-289, Saunders, Philadelphia, 2007.
3) Fowler JE, et al : Presentation, diagnosis and treatment of renal abscesses : 1972-1988. J Urol 151 : 847-851, 1994.
4) Brandeis JM, et al : Recurrent Staphylococcus aureus renal abscess in a child positive for the human immunodeficiency virus. Urology 46 : 246-248, 1995.
5) Campbell MF : Perinephritic abscess. Surg Gynecol Obstet 51 : 674-682, 1930.
8) Truesdale BH, et al : Perinephric abscess : a review of 26 cases. J Urol 118 : 910-911, 1977.
9) Plevin SN, et al : Perinephric abscess in diabetic patients. J Urol 103 : 538-543, 1970.
10) Sweet R, Keane WF : Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron 23 : 237-240, 1979.
12) Salvatierra O, et al : Perinephric abscess : a report of 71 cases. J Urol 98 : 296-302, 1967.
13) Morgan WR, et al : Perinephric and intrarenal abscesses. Urology 26 : 529-536, 1985.
P.388 掲載の参考文献
1) Peters CJ, et al : Spectrum of hantavirus infection : hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 50 : 531-545, 1999.
2) Abudurexiti A, et al : Taxonomy of the order Bunyavirales : update 2019. Arch Virol 164 : 1949-1965, 2019.
3) McCormick JB, et al : Morphological identification of the agent of Korean haemorrhagic fever (Hantaan virus) as a member of the Bunyaviridae. Lancet 1 : 765-768, 1982.
4) Schmaljohn CS, et al : Characterization of Hantaan virions, the prototype virus of hemorrhagic fever with renal syndrome. J Infect Dis 148 : 1005-1012, 1983.
5) Lee HW, et al : Isolation of the etiologic agent of Korean Hemorrhagic fever. J Infect Dis 137 : 298-308, 1978.
6) Zhang YZ : Discovery of hantaviruses in bats and insectivores and the evolution of the genus Hantavirus. Virus Res 187 : 15-21, 2014.
7) Song G, et al : Antigenic difference between viral strains causing classical and mild types of epidemic hemorrhagic fever with renal syndrome in China. J Infect Dis 150 : 889-894, 1984.
8) Kruger DH, et al : Hantaviruses-globally emerging pathogens. J Clin Virol 64 : 128-136, 2015.
9) Lee HW, et al : Intraspecific transmission of Hantaan virus, etiologic agent of Korean hemorrhagic fever, in the rodent Apodemus agrarius. Am J Trop Med Hyg 30 : 1106-1112, 1981.
10) Lee HW, Johnson KM : Laboratory-acquired infections with Hantaan virus, the etiologic agent of Korean hemorrhagic fever. J Infect Dis 146 : 645-651, 1982.
11) Lee HW, et al : Etiological relation between Korean hemorrhagic fever and epidemic hemorrhagic fever in Japan. Biken J 22 : 41-45, 1979.
12) Kawamata J, et al : Control of laboratory acquired hemorrhagic fever with renal syndrome (HFRS) in Japan. Lab Anim Sci 37 : 431-436, 1987.
13) Arikawa J, et al : Epidemiology and epizootiology of hantavirus infection in Japan. Jpn J Infect Dis 54 : 95-102, 2001.
14) Kariwa H, et al : Evidence for the existence of Puumula-related virus among Clethrionomys rufocanus in Hokkaido, Japan. Am J Trop Med Hyg 53 : 222-227, 1995.
15) 李文鎬 : 韓国型出血熱-腎症候性出血熱 (山本祐夫訳), p32-49, 近代出版, 1983.
16) Yoshimatsu K, et al : Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic antigen in detecting antibodies in serum from infected rats. Lab Anim Sci 45 : 641-646, 1995.
17) Morii M, et al : Antigenic characterization of Hantaan and Seoul virus nucleocapsid proteins expressed by recombinant baculovirus : application of a truncated protein, lacking an antigenic region common to the two viruses, as a serotyping antigen. J Clin Microbol 36 : 2514-2521, 1998.
18) Amada T, et al : Rapid, whole blood diagnostic test for detecting anti-hantavirus antibody in rats. J Virol Methods 193 : 42-49, 2013.
19) Takakura A, et al : Establishment of an enzyme-linked immunosorbent assay for detection of hantavirus antibody of rats using a recombinant of nucleocapsid protein expressed in Escherichia coli. Exp Anim 52 : 25-30, 2003.
P.393 掲載の参考文献
1) Sobel JD, et al : Guidelines for the treatment of fungal urinary tract infections. In : Urological infection. Edition 2010 (ed by Naber KG, et al), p903-911, European Association of Urology, Stockholm, 2010.
2) Gajdacs M, et al : Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients : results from a 10-year retrospective survey. Cent European J Urol 72 : 209-214, 2019.
3) Sobel JD, et al : Candida urinary tract infections--epidemiology. Clin Infect Dis 52 (Suppl 6) : S433-436, 2011.
4) Fisher JF : Candida urinary tract infections--epidemiology, pathogenesis, diagnosis, and treatment : executive summary. Clin Infect Dis 52 (Suppl 6) : S429-432, 2011.
5) Alvarez-Lerma F, et al : Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med 29 : 1069-1076, 2003.
6) Bougnoux ME, et al : Candidemia and candiduria in critically ill patients admitted to intensive care units in France : incidence, molecular diversity, management and outcome. Intensive Care Med 34 : 292-299, 2008.
7) Phillips JR, Karlowicz MG : Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit. Pediatr Infect Dis J 16 : 190-194, 1997.
8) Shay AC, Miller LG : An estimate of the incidence of Candiduria among hospitalized patients in the United States. Infect Control Hosp Epidemiol 25 : 894-895, 2004.
9) Fisher JF, et al : Candida urinary tract infection : pathogenesis. Clin Infect Dis 52 (Suppl 6) : S437-451, 2011.
10) 濱砂良一, 松本哲朗 : カンジダ属による尿路感染症の治療. IDSAガイドライン-真菌症治療のUP-TO-DATE (河野茂編), p133-138, 医薬ジャーナル社, 2010.
11) 日本医真菌学会侵襲性カンジダ症の診断・治療ガイドライン作成委員会 : 日本医真菌学会侵襲性カンジダ症の診断・治療ガイドライン 2013, 日本医真菌学会, 2013.
12) Fisher JF, et al : Candida urinary tract infections-treatment. Clin Infect Dis 52 (Suppl 6) : S457-466, 2011.
13) Abdeljaleel OA, et al : Treatment of Renal Fungal Ball with Fluconazole Instillation Through a Nephrostomy Tube : Case Report and Literature Review. Am J Case Rep 19 : 1179-1183, 2018.
14) Abuelnaga M, et al : Successful Endoscopic Management of a Renal Fungal Ball using Flexible Ureterorenoscopy. Case Rep Urol 2019 : 9241928, 2019.
P.398 掲載の参考文献
2) Dellinger RP, et al : Surviving Sepsis Campaign : international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39 : 165-228, 2013.
3) Bagshaw SM, et al : Septic acute kidney injury in critically ill patients : clinical characteristics and outcomes. Clin J Am Soc Nephrol 2 : 431-439, 2007.
4) Bellomo R, et al : Acute kidney injury in sepsis. Intensive Care Med 43 : 816-828, 2017.
5) Angus DC, et al : Epidemiology of severe sepsis in the United States : analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 : 1303-1310, 2001.
6) Vincent JL, et al : Sepsis in European intensive care units : results of the SOAP study. Crit Care Med 34 : 344-353, 2006.
7) Poukkanen M, et al : Acute kidney injury in patients with severe sepsis in Finnish Intensive Care Units. Acta Anaesthesiol Scand 57 : 863-872, 2013.
9) Aslan A, et al : Kidney histopathology in lethal human sepsis. Crit Care 22 : 359, 2018.
10) Knotek M, et al : Endotoxemic renal failure in mice : Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 59 : 2243-2249, 2001.
11) Langenberg C, et al : The histopathology of septic acute kidney injury : a systematic review. Crit Care 12 : R38, 2008.
14) Haase M, et al : Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury : a systematic review and meta-analysis. Am J Kidney Dis 54 : 1012-1024, 2009.
15) Bagshaw SM, et al : Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 36 : 452-461, 2010.
16) Martensson J, et al : Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 36 : 1333-1340, 2010.
17) Susantitaphong P, et al : Performance of urinary liver-type fatty acid-binding protein in acute kidney injury : a meta-analysis. Am J Kidney Dis 61 : 430-439, 2013.
18) Liu Y, et al : Urinary interleukin 18 for detection of acute kidney injury : a meta-analysis. Am J Kidney Dis 62 : 1058-1067, 2013.
19) Shao X, et al : Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury : a meta-analysis. PLoS One 9 : e84131, 2014.
20) Alge JL, Arthur JM : Biomarkers of AKI : a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol 10 : 147-155, 2015.
21) Kuttab HI, et al : Evaluation and Predictors of Fluid Resuscitation in Patients With Severe Sepsis and Septic Shock. Crit Care Med 47 : 1582-1590, 2019.
22) Boyd JH, et al : Fluid resuscitation in septic shock : a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39 : 259-265, 2011.
23) Bouchard J, et al : Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 76 : 422-427, 2009.
24) Payen D, et al : A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 12 : R74, 2008.
P.406 掲載の参考文献
1) Corrado ML, et al : Norfloxacin in the treatment of urinary tract infections in men with and without identifiable urologic complications. Am J Med 82 : 70-74, 1987.
2) Chen SS, et al : Complicated urinary tract infection : analysis of 179 patients. Zhonghua Yi Xue Za Zhi (Taipei) 61 : 651-656, 1998.
3) Johnson DE, et al : Urethral obstruction of 6 hours or less causes bacteriuria, bacteremia, and pyelonephritis in mice challenged with "nonuropathogenic" Escherichia coli. Infect Immun 61 : 3422-3428, 1993.
4) Hamasuna R, et al : Obstructive pyelonephritis as a result of urolithiasis in Japan : diagnosis, treatment and prognosis. Int J Urol 22 : 294-300, 2015.
5) Ishikawa Y, et al : Prognostic Accuracy of the qSOFA Score for In-Hospital Mortality in Elderly Patients with Obstructive Acute Pyelonephritis : A Multi-Institutional Study. Diagnostics (Basel) 11 : 2277, 2021.
6) Mann U, et al : Predictors of mortality for patients admitted to the intensive care unit with obstructing septic stones. Can Urol Assoc J 15 : E593-E597, 2021.
7) Kobayashi K, et al : The third national Japanese antimicrobial susceptibility pattern surveillance program : Bacterial isolates from complicated urinary tract infection patients. J Infect Chemother 26 : 418-428, 2020.
8) Heyns CF : Urinary tract infections in obstruction of the urinary tract. In : Urological Infection, Edition 2010 (ed by Naber KG, et al), p452-480, European Association of Urology, Stockholm, 2010.
9) Bautista OM, et al : Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 24 : 224-243, 2003.
10) McConnell JD, et al : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 : 2387-2398, 2003.
11) Hamasuna R, et al : Guideline for the prevention of health care-associated infection in urological practice in Japan. Int J Urol 18 : 495-502, 2011.
12) Song SH, et al : Is antibiotic prophylaxis necessary in infants with obstructive hydronephrosis? J Urol 177 : 1098-1101 ; discussion 1101, 2007.
13) Coelho GM, et al : Risk factors for urinary tract infection in children with prenatal renal pelvic dilatation. J Urol 179 : 284-289, 2008.
P.411 掲載の参考文献
1) 尾田高志 : 感染症と腎炎. 日本内科学会雑誌 109 : 903-909, 2020.
2) Satoskar AA, et al : Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol 16 : 32-50, 2020.
3) Ilyas M, Tolaymat A : Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida : a comparative study. Pediatr Nephrol 23 : 1101-1106, 2008.
6) Oda T, Yoshizawa N : Factors Affecting the Progression of Infection-Related Glomerulonephritis to Chronic Kidney Disease. Int J Mol Sci 22 : 905, 2021.
8) Rodriguez-Iturbe B, Batsford S : Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 71 : 1094-1104, 2007.
10) Kanazawa N, et al : A case of acute poststreptococcal glomerulonephritis complicated by interstitial nephritis related to streptococcal pyrogenic exotoxin B. Pathol Int 72 : 200-206, 2022.
11) Fremeaux-Bacchi V, et al : Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 9 : 1747-1750, 1994.
12) Chauvet S, et al : Anti-Factor B Antibodies and Acute Postinfectious GN in Children. J Am Soc Nephrol 31 : 829-840, 2020.
13) Becquet O, et al : Acute post-streptococcal glomerulonephritis in children of French Polynesia : a 3-year retrospective study. Pediatr Nephrol 25 : 275-280, 2010.
14) 小島亜希, 尾田高志 : 溶連菌感染後急性糸球体腎炎. 腎臓内科 14 : 653-658, 2021.
15) Inoue D, et al : Thrombotic microangiopathy with transiently positive direct Coombs test in an adult with poststreptococcal acute glomerulonephritis : a case report. BMC Nephrol 23 : 56, 2022.
P.417 掲載の参考文献
1) Husby G : Amyloidosis. Semin Arthritis Rheum 22 : 67-82, 1992.
2) Nishi S, et al : New advances in renal amyloidosis. Clin Exp Nephrol 12 : 93-101, 2008.
3) わが国の慢性透析療法の現況 (2020年12月31日現在). [https://docs.jsdt.or.jp/overview/file/2020/add/03.pdf]
4) Nishi S, et al : A clinical evaluation of renal amyloidosis in the Japan renal biopsy registry : a cross-sectional study. Clin Exp Nephrol 21 : 624-632, 2017.
5) Grcevska L, et al : Primary amyloidosis-involving principally intrarenal blood vessels. Nephrol Dial Transplant 8 : 296-300, 1993.
6) Mumford AD, et al : Bleeding symptoms and coagulation abnormalities in 337 patients with ALamyloidosis. Br J Haematol 110 : 454-460, 2000.
7) Quock TP, et al : Epidemiology of AL amyloidosis : a real-world study using US claims data. Blood Adv 2 : 1046-1053, 2018.
8) Shimazaki C, et al : Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan. Intern Med 57 : 181-187, 2018.
9) Tang W, et al : End-stage renal failure due to amyloidosis : outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant 28 : 455-461, 2013.
11) Sanchorawala V, et al : Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis : results of a phase 2 study. Blood 135 : 1541-1547, 2020.
12) Hoshino J, et al : Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis. NDT Plus 1 : 414-416, 2008.
14) Rocha A, Lobato L : Liver transplantation in transthyretin amyloidosis : Characteristics and management related to kidney disease. Transplant Rev (Orlando) 31 : 115-120, 2017.
P.421 掲載の参考文献
1) Berger KW, Relman AS : Renal impairment due to sarcoid infiltration of the kidney ; report of a case proved by renal biopsies before and after treatment with cortisone. N Engl J Med 252 : 44-49, 1955.
2) Lhote R, et al : Clinical phenotypes of extrapulmonary sarcoidosis : an analysis of a French, multiethnic, multicentre cohort. Eur Respir J 57 : 2001160, 2021.
3) Berliner AR, et al : Sarcoidosis : the nephrologist's perspective. Am J Kidney Dis 48 : 856-870, 2006.
4) Baughman RP, et al : Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164 : 1885-1889, 2001.
5) 森本泰介, ほか : 2004年サルコイドーシス疫学調査. サルコイドーシス/肉芽腫性疾患 27 : 103-108, 2007.
6) 岩井和郎, ほか : サルコイドーシス剖検例の統計的・病理学的観察. 日本胸部疾患学会雑誌 11 : 749-763, 1979.
7) 三上理一郎, ほか : サルコイドージス. 日本臨牀 41 (春季増刊 : 本邦臨床統計集) : 1443-1471, 1983.
9) Crowley LE, et al : "Sarcoid like" granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med 54 : 175-184, 2011.
10) Loffler C, et al : Renal sarcoidosis : epidemiological and follow-up data in a cohort of 27 patients. Sarcoidosis Vasc Diffuse Lung Dis 31 : 306-315, 2015.
11) Kamphuis LS, et al : Calcium and vitamin D in sarcoidosis : is supplementation safe? J Bone Miner Res 29 : 2498-2503, 2014.
12) Inui N, et al : Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med 110 : 687-693, 2001.
13) 四十坊典晴, 山口哲生 : わが国におけるサルコイドーシスの診断基準と重症度分類. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 35 : 3-8, 2015.
14) Iannuzzi MC, Fontana JR : Sarcoidosis : clinical presentation, immunopathogenesis, and therapeutics. JAMA 305 : 391-399, 2011.
P.426 掲載の参考文献
1) Hariharan S, et al : Long-Term Survival after Kidney Transplantation. N Engl J Med 385 : 729-743, 2021.
2) 石井大輔, ほか : ファクトブック 2021-Fact Book 2021 on Organ transplantation in Japan, p36-48, 日本移植学会, 2021.
3) Cosio FG, Cattran DC : Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int 91 : 304-314, 2017.
4) 升谷耕介 : 移植後再発腎炎 up to date. 日本臨床腎移植学会雑誌 7 : 57-63, 2019.
5) Blosser CD, Bloom RD : Recurrent glomerular disease after kidney transplantation. Curr Opin Nephrol Hypertens 26 : 501-508, 2017.
6) Jiang SH, et al : Recurrent glomerulonephritis following renal transplantation and impact on graft survival. BMC Nephrol 19 : 344, 2018.
7) Uffing A, et al : Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. Clin J Am Soc Nephrol 16 : 1247-1255, 2021.
8) Wyld ML, Chadban SJ : Recurrent IgA Nephropathy After Kidney Transplantation. Transplantation 100 : 1827-1832, 2016.
9) Leeaphorn N, et al : Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens : a retrospective analysis of the UNOS/OPTN database. Transpl Int 31 : 175-186, 2018.
10) Koshino K, et al : Outcome of tonsillectomy for recurrent IgA nephropathy after kidney transplantation. Clin Transplant 27 (Suppl 26) : 22-28, 2013.
11) Messina M, et al : Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation. J Nephrol 29 : 575-583, 2016.
12) Uffing A, et al : Recurrence of FSGS after Kidney Transplantation in Adults. Clin J Am Soc Nephrol 15 : 247-256, 2020.
13) Marinaki S, et al : Glomerular disease recurrence in the renal allograft : a hurdle but not a barrier for successful kidney transplantation. Transplant Proc 45 : 3-9, 2013.
14) Coche S, et al : Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation. Kidney Int Rep 6 : 1888-1894, 2021.
P.431 掲載の参考文献
1) Stahl K, et al : A systematic review on the definition of rhabdomyolysis. J Neurol 267 : 877-882, 2020.
2) Chong WH, Saha BK : Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI). Am J Med Sci 361 : 287-296, 2021.
3) Gupta A, et al : Rhabdomyolysis : Revisited. Ulster Med J 90 : 61-69, 2021.
4) Sheng ZY : Medical support in the Tangshan earthquake : a review of the management of mass casualties and certain major injuries. J Trauma 27 : 1130-1135, 1987.
5) Ukai T : The Great Hanshin-Awaji Earthquake and the problems with emergency medical care. Ren Fail 19 : 633-645, 1997.
6) Bagley WH, et al : Rhabdomyolysis. Intern Emerg Med 2 : 210-218, 2007.
7) de Meijer AR, et al : Serum creatine kinase as predictor of clinical course in rhabdomyolysis : a 5-year intensive care survey. Intensive Care Med 29 : 1121-1125, 2003.
10) Corwin HL, et al : Low fractional excretion of sodium. Occurrence with hemoglobinuric- and myoglobinuric-induced acute renal failure. Arch Intern Med 144 : 981-982, 1984.
11) Zager RA : Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest 90 : 711-719, 1992.
12) Belliere J, et al : Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury. J Am Soc Nephrol 26 : 1363-1377, 2015.
13) Okubo K, et al : Macrophage extracellular trap formation promoted by platelet activation is a key mediator of rhabdomyolysis-induced acute kidney injury. Nat Med 24 : 232-238, 2018.
14) Zarjou A, et al : Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest 123 : 4423-4434, 2013.
15) Michelsen J, et al : Prevention of rhabdomyolysis-induced acute kidney injury-A DASAIM/DSIT clinical practice guideline. Acta Anaesthesiol Scand 63 : 576-586, 2019.
P.435 掲載の参考文献
2) Stewart PM, et al : Mineralocorticoid activity of liquorice : 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2 : 821-824, 1987.
3) 森本靖彦, 中島智子 : 甘草製剤による偽アルドステロン症のわが国における現状. 和漢医薬学会誌 8 : 1-22, 1991.
4) 厚生労働省 : 偽アルドステロン症. 重篤副作用疾患別対応マニュアル (第二版), 2021.
5) 柴田洋孝 : 偽性アルドステロン症. 日本内科学会雑誌 95 : 671-676, 2006.
6) 柴田洋孝, 伊藤裕 : 偽性アルドステロン症の重症副作用への疾患別対応. 日本内科学会雑誌 96 : 805-810, 2007.
7) 宗友厚 : 偽性アルドステロン症 ; 副腎. アルドステロン異常症. 原発性アルドステロン症および類縁疾患. 別冊日本臨牀領域別症候群シリーズ No.2 内分泌症候群 (第3版) II, p121-125, 2018.
9) 宗友厚 : 11βHSD タイプ 2 欠損症 (AME 症候群) ; 副腎. アルドステロン異常症. 原発性アルドステロン症および類縁疾患. 別冊日本臨牀領域別症候群シリーズ No.2 内分泌症候群 (第3版) II, p131-135, 2018.
10) Yoshino T, et al : Clinical Risk Factors of Licorice-Induced Pseudoaldosteronism Based on Glycyrrhizin-Metabolite Concentrations : A Narrative Review. Front Nutr 8 : 719197, 2021.
11) Kato H, et al : 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J Clin Endocrinol Metab 80 : 1929-1933, 1995.
12) Makino T : Exploration for the real causative agents of licorice-induced pseudoaldosteronism. J Nat Med 75 : 275-283, 2021.
13) 杉田実, ほか : 甘草によるpseudoaldosteronismの1症例. 日本内科学会雑誌 63 : 1312, 1974.
P.440 掲載の参考文献
1) Kakehi E, et al : Kimura's disease : effects of age on clinical presentation. QJM 113 : 336-345, 2020.
2) Ren S, et al : Nephrotic syndrome associated with Kimura's disease : a case report and literature review. BMC Nephrol 19 : 316, 2018.
3) Yang S, et al : Concurrent Kidney Glomerular and Interstitial Lesions Associated with Kimura's Disease. Nephron 143 : 92-99, 2019.
4) Matsuo T, et al : Nephrotic syndrome during the tapering of oral steroids after pathological diagnosis of Kimura disease from a lacrimal gland mass. case report and review of 10 Japanese patients. J Clin Exp Hematop 57 : 147-152, 2017.
5) Abuel-Haija M, Hurford MT : Kimura disease. Arch Pathol Lab Med 131 : 650-651, 2007.
6) Chen H, et al : Kimura Disease : A Clinicopathologic Study of 21 Cases : Am J Surg Pathol 28 : 505-513, 2004.
7) Wang X, et al : A comparative study of Kimura's disease and IgG4-related disease : similarities, differences and overlapping features. Histopathology 79 : 801-809, 2021.
8) Terada N, et al : Mechanism of eosinophil infiltration in the patient with subcutaneous angioblastic lymphoid hyperplasia with eosinophilia (Kimura's disease). Mechanism of eosinophil chemotaxis mediated by candida antigen and IL-5. Int Arch Allergy Immunol 104 (Suppl 1) : 18-20, 1994.
9) Katagiri K, et al : In vivo expression of IL-4, IL-5, IL-13 and IFN-gamma mRNAs in peripheral blood mononuclear cells and effect of cyclosporin A in a patient with Kimura's disease. Br J Dermatol 137 : 972-977, 1997.
10) Kimura Y, et al : Mast cells and T cells in Kimura's disease express increased levels of interleukin-4, interleukin-5, eotaxin and RANTES. Clin Exp Allergy 32 : 1787-1793, 2002.
11) Munemura R, et al : Distinct disease-specific Tfh cell populations in 2 different fibrotic diseases : IgG4-related disease and Kimura disease. J Allergy Clin Immunol 150 : 440-455.e17, 2022.
12) Kinoshita M, et al : Mepolizumab-responsive Kimura disease. J Allergy Clin Immunol Pract 9 : 2928-2930, 2021.
13) Lin YY, et al : Kimura's disease : clinical and imaging parameters for the prediction of disease recurrence. Clin Imaging 36 : 272-278, 2012.
14) Chen QL, et al : Kimura's disease : risk factors of recurrence and prognosis. Int J Clin Exp Med 8 : 21414-21420, 2015.
P.445 掲載の参考文献
1) Jodele S, et al : Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy : a study in children and young adults. Blood 124 : 645-653, 2014.
2) Jodele S, et al : A new paradigm : Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29 : 191-204, 2015.
6) Glezerman IG, et al : Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16 : 976-984, 2010.
7) 造血細胞移植ガイドラインSOS/TA-TMA (第2版) (令和2 学会年度日本造血・免疫細胞療法学会ガイドライン委員会編), p16-25, 日本造血・免疫細胞療法学会, 2022.
8) Nakamae H, et al : Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 81 : 525-531, 2006.
9) Uderzo C, et al : Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 82 : 638-644, 2006.
10) Seeber C, et al : Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNFα) -release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb Res 66 : 373-383, 1992.
12) Laskin BL, et al : Renal arteriolar C4d deposition : a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 96 : 217-223, 2013.
15) Matsui H, et al : Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv 4 : 3169-3179, 2020.
P.450 掲載の参考文献
1) 小田桐玲子, ほか : Foam Cell Syndromeの2例. 内科 26 : 965-971, 1970.
2) 三浦亮 : Foam cell syndrome (泡沫細胞症候群). 日本臨牀 40 (増刊 : 症候群 1982-概念の変遷とその今日的意義-血液・造血器) : 512-513, 1982.
3) 竹森信男, ほか : Hydroxyethyl Starch (HES) 過剰投与に基づくと考えられた泡沫細胞症候群の2例. 日本網内系学会会誌 22 : 142-153, 1982.
4) 浜中純子, ほか : Hydroxyethyl starch (HES) の大量投与による泡沫細胞症候群の1例. 最新医学 39 : 2392-2397, 1984.
5) Schmidt-Heiber M, et al : Hydrops lysosomalis generalisatus-an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 77 : 83-85, 2006.
6) Auwerda JJ, et al : Foamy macrophage syndrome due to hydroxyethyl starch replacement : a severe side effect in plasmapheresis. Ann Intern Med 137 : 1013-1014, 2002.
7) 吉野正, ほか : 低分子量代用血漿剤 (デキストランおよびHES剤) 投与により惹起された泡沫細胞症候群の1例. 病理と臨床 5 : 1237-1242, 1987.
8) Bergonzi G, et al : Dextran deposits in tissues of patients undergoing haemodialysis. Nephrol Dial Transplant 5 : 54-58, 1990.
9) Wiedermann CJ, et al : Accumulation of hydroxyethyl starch in human and animal tissues : a systematic review. Intensive Care Med 40 : 160-170, 2014.
10) Nomani AZ, et al : Osmotic nephrosis with mannitol : review article. Ren Fail 36 : 1169-1176, 2014.
P.455 掲載の参考文献
1) Esterly NB, et al : Bullous pemphigoid and membranous glomerulonephropathy in a child. J Pediatr 83 : 466-470, 1973.
2) 武曾惠理, ほか : 類天疱瘡 ; 各種病態にみられる腎障害. その他の病態. 別冊日本臨牀新領域別症候群シリーズ No. 18 腎臓症候群 (第2版) 下, p797-800, 日本臨牀社, 2012.
3) 清水宏 : 表皮. あたらしい皮膚科学 [第2版], p3-7, 中山書店, 2011.
4) 飯田孝志, ほか : 水疱性類天疱瘡の病変部皮膚における基底膜部成分の発現. 日本皮膚科学会雑誌 109 : 1571-1579, 1999.
5) Ujiie H, et al : Bullous pemphigoid autoantibodies directly induce blister formation without complement activation. J Immunol 193 : 4415-4428, 2014.
6) Hoorn EJ, Taams NE : Bullous Pemphigoid With a Dual Pattern of Glomerular Immune Complex Disease. Am J Kidney Dis 67 : 302-306, 2016.
7) Soine EJ, et al : A patient with coexistent bullous pemphigoid and primary membranous glomerulonephropathy. J Am Acad Dermatol 60 : 1042-1044, 2009.
8) 難病情報センター : 類天疱瘡 (後天性表皮水疱症を含む.) ; 病気の解説・診断基準・臨床調査個人票の一覧 [https://www.nanbyou.or.jp/wp-content/uploads/upload_files/File/162-201704-kijyun.pdf]
9) Ikeda M, et al : Membranous glomerulonephropathy in a patient with bullous pemphigoid. CEN Case Rep 6 : 50-54, 2017.
10) Mereniuk E, et al : A Case of Severe and Refractory Membranous Nephropathy Associated to Mucous Membrane Pemphigoid. Case Rep Nephrol 2021 : 9940293, 2021.
12) Plaisier E, et al : Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-α3 (IV) NC1 and anti-BP180 antibodies in a patient with Crohn's disease. Am J Kidney Dis 40 : 649-654, 2002.
13) Schmidt E, Zillikens D : Immunoadsorption in dermatology. Arch Dermatol Res 302 : 241-253, 2010.

最近チェックした商品履歴

Loading...